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A method of detecting a target biochemical molecular species or at least one property 
correlated with the occurrence of the biochemical molecular species in a sample whose main 
component is water. The method includes: obtaining a sample whose main component is 
water; providing Functionalized Paramagnetic Particles (FPP) including a paramagnetic core 
and a moiety configured to interact with the target biochemical molecular species or with 
molecules collectively reporting on a property of the target biochemical molecular species; 
contacting the FPP with the sample; exposing the sample to an applied magnetic field; 
measuring a change in a nuclear relaxation property of the sample; and correlating the change 
to the presence of the biochemical molecular species in the sample or to at least one property 
correlated with the occurrence of the biochemical molecular species in the sample. 
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Description 
FIELD OF THE INVENTION 
The present invention relates to the field of magnetic resonance-based systems and related 
methods, for diagnostic in vitro applications, and more particularly, to systems that use 
magnetic resonance 1H-relaxometry for detection of a biomarker of interest and methods 
thereof. 
BACKGROUND OF THE INVENTION 
Biomarkers are objective measures or indicators which are used to evaluate disease versus 
normal biological processes or responses to a drug or treatment. Many different biomarker 
types are utilized for various purposes in the pharmaceutical process. Biomarker types and 
applications thereof are broadly used in the clinical and healthcare spectrum, for example 
biomarkers for risk assessment, permit the estimation of the risk of an individual to develop a 
particular disease. Other types of biomarkers include: biomarkers for earlier and more 
specific indication of a compound's toxicity; biomarkers for prognosis (providing information 
about the expected course of a disease); biomarkers for patient stratification (allowing to 
identify the best treatment for a disease); and, biomarkers for therapy monitoring (providing 
information at an early stage as to whether treatment is working or if the disease is getting 
worse). 
Biosensing strategies using magnetic nanoparticles have been reported in the relevant art. 
These publications describe magnetic resonance-related techniques based on T2-relaxation 
time measurements. For example, US application No. 2011/0091987A1 and a recently 
published scientific article (Huilin Shao et al., Theranostics 2012) describe NMR-based 
detection mechanism for diagnostic applications. In order to increase the sensitivity of the 
detection, magnetic nanoparticles have been used that are specifically designed and shown to 
improve T2* changes. These particles consist of ferrite particles or crossed linked iron oxide. 
Thus, there is still a long felt need to provide sensitive and reliable means and methods for 
the identification and quantification of a biomarker of interest for diagnostic applications. 
SUMMARY OF THE INVENTION 
It is an object of the present invention to disclose a method for detecting a target biochemical 
molecular species or at least one property correlated with the occurrence of said biochemical 
molecular species in a sample whose main component is water, comprising;  
 a. obtaining a sample whose main component is water; 
 a. providing Functionalized Paramagnetic Particles (FPP) comprising a paramagnetic 
core and a moiety configured to interact with said target biochemical molecular 
species or with molecules collectively reporting on a property of said target 
biochemical molecular species; 
 a. contacting said FPP with said sample; 
 a. exposing said sample to an applied magnetic field; and, 
 a. measuring a change in a nuclear relaxation property of said sample, caused by said 
interaction between said FPP and said biochemical molecular species or said 
molecules collectively reporting on a property of said target biochemical molecular 
species; in the applied magnetic field; and, 
 a. correlating said change to the presence of said biochemical molecular species in 
said sample or to at least one property correlated with the occurrence of said 
biochemical molecular species in said sample;  
wherein a change in T.sub.1 nuclear relaxation property of the water protons in said 
sample is correlated to the presence of said target biochemical molecular species or to 
at least one property correlated with the occurrence of said biochemical molecular 
species in said sample, further wherein said FPP comprises a non ferrous oxide 
paramagnetic core.  
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of performing two or more measurements to determine the 
relaxation time of the sample, wherein the measurements are performed before and after at 
least one addition of said FPP. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of detecting said target biochemical molecular species and/or 
characterizing at least one property correlated with the occurrence of said biochemical 
molecular species in vitro. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of forming said FPP as a single molecule, a multimeric system, 
a micro-sized vesicle or particle, a nano-sized vesicle or particle, a liposome, a probe or any 
combination thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said sample from a group consisting of a liquid, a 
gas, a slurry, a liquid containing particulates, a gas containing particulates, a gel, a sol, a 
suspension, a solution, a dispersion, a colloid, a mixture, an emulsion, an aerosol, a liquid 
containing solid objects, a gas containing solid objects, and any combination thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said sample from a group comprising a biological 
fluid, a biological tissue, a tissue extract, an industrial fluid, food sample, a beverage, wine, 
water, potable water, sewage, irrigation water, sea water, river water, lake water, industrial 
effluent, farm effluent, effluent from human habitation, road runoff, cleaning fluid, a gas 
sample or any combination thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said biological fluid from a group comprising 
urine, blood, lymph, plasma, cerebrospinal fluid, saliva, amniotic fluid, bile and tears. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of providing said sample within a production process. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said production process in an industrial area, said 
industrial area is a member of a group consisting of the pharmaceuticals, food production, 
beverage production, chemical refining, chemical processing, medical products, biological 
products, metal casting, metal refining, desalination, fluid purification, and sewage 
processing. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of analyzing at least one characteristic or property of said target 
molecular species, said characteristic or property is selected from a group comprising 
concentration, permeability, oxidation state, redox characteristic (reduction-oxidation state), 
activation state and any combination thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of applying a magnetic field, thereby enhancing the change in a 
paramagnetic nuclear relaxation property of said sample upon comparing relaxation rates at 
two different magnetic fields. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of measuring a change in a nuclear relaxation property of said 
sample using a portable NMR or MRI measuring means. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of measuring a change in a nuclear relaxation property of said 
sample using a magnetic resonance device (MRD) consisting of magnets housed within a 
cage. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of measuring a change in a nuclear relaxation property of said 
sample using a self-fastening cage type of a magnetic resonance device (MRD). 
It is another object of the present invention to disclose the method as defined above, In a self-
fastening cage of a magnetic resonance device (MRD) (300), a method according to claim 1 
comprising an additional step of providing a homogeneous, stable and uniform magnetic field 
therein, further wherein said self-fastening cage type MRD additionally characterized by an 
outside shell comprising at least three flexi-jointed superimposed walls (1). 
It is another object of the present invention to disclose in a self-fastening cage type MRD 
(300), a method as defined above comprising an additional step of providing an MRD 
characterized by an outside shell; said outside shell comprising at least three flexi-jointed 
superimposed walls (1) disposed in a predetermined clockwise or counterclockwise 
arrangement; said MRD comprising:  
 a. at least six side-magnets (2) arranged in two equal groups being in a face-to-face 
orientation in a magnetic connection with said outside shell, increasing the overall 
strength of the magnetic field provided in said cage; 
 b. at least two pole-magnet pieces (3), arranged in a face-to-face orientation in 
between said side-magnets (2); 
 c. at least two main-magnets (4), located on said pole-pieces (3), arranged in a face-
to-face orientation, generating the static magnetic field therein said cage; and, 
 d. shimming mechanism, said mechanism is selected from a group consisting of an 
array of active shim coils, passive shimming elements or a combination thereof;  
wherein at least a portion of said side-magnets (2) are superconductors or 
ferromagnets.  
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of providing a magnetic resonance device adapted to producing 
high contrast high resolution images of said sample. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of providing a magnetic resonance device comprising:  
 a. an envelope for least partially confining said sample; 
 b. a plurality of magnets located at least partially around said envelope, said plurality 
of magnets comprising:  
o i. a least one first magnet configured to provide a high magnetic field for 
generating multiple time-resolved one or more first images at high resolution 
of at least a portion of said sample; and 
o ii. a least one second magnet configured to provide a low magnetic field for 
generating multiple time-resolved one or more second images at high contrast 
of at least portion of same said sample; wherein at least one image of said first 
images and at least one image of said second images being generated in a time 
no greater than approximately the time between two first images; and, 
 c. a CPU to process said images comprising a computer readable medium containing 
instructions for generating at least one third image superimposing at least one image 
of said first images with at least one image of said second images. 
It is another object of the present invention to disclose the method as defined above, 
comprising additional steps of  
 a. generating multiple time resolved one or more first images at high resolution of at 
least a portion of said sample; 
 b. generating multiple time resolved one or more second images at high contrast of at 
least portion of same said sample; and 
 c. superimposing at least one image of said first images with at least one image of said 
second images;  
whereby a high-contrast, high resolution real-time continuous image of said sample is 
obtained.  
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said at least one first magnet to be of 2 Tesla and 
lower. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said at least one first magnet to be of 2 Tesla and 
higher. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said at least one first magnet from a group 
consisting of permanent magnets, electromagnets, superconducting magnets, and any 
combination thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said at least one second magnet to be of 2 Tesla 
and lower. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said at least one second magnet to be of 2 Tesla 
and higher. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said at least one second magnet from a group 
consisting of permanent magnets, electromagnets, superconducting magnets, and any 
combination thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of generating a magnetic resonance signal in the range of about 
0.1 Tesla and about 10 Tesla. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of generating a magnetic resonance signal in the range of 2 
Tesla and lower. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of generating a magnetic resonance signal in the range of 2 
Tesla and higher. 
It is another object of the present invention to disclose the method as defined above, further 
comprises steps of applying a magnetic resonance frequency in the range of about 5 MHz to 
about 40 MHz. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said magnets from a group consisting of permanent 
magnets, electromagnets, superconducting magnets, and any combination thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said moiety from a group comprising antibodies, 
antibody fragments, monoclonal antibody, receptors, ligands, macromolecules, peptides, 
hormones, fatty acids, lipids, receptor agonists and antagonists, amino acids, sugars, lectins, 
albumins, polycarbon molecules, glycoproteins, nucleic acids, pegylated molecules, 
liposomes, chelators, cells, viruses, chemotherapeutic agents and any combination thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said target biochemical molecular species from a 
group comprising a biological molecule, a chemical molecule, an analyte, a contaminant, a 
particle, a pathogen or any combination thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said target biochemical molecular species from a 
group comprising a protein, a pathogen, a prion, a virus, a bacteria, a contaminant, a 
pathological isoform, a biomarker, an allergen, a neurotransmitter, an antigenic determinant, 
an epitope, a cell marker, cell membrane marker or epitope, a membrane marker, an enzyme, 
a chemical molecule, an analyte, a receptor, a ligand, a macromolecule, a peptide, a hormone, 
a fatty acid, a lipid, a receptor agonist and antagonist, an amino acid, a sugar, a glycoprotein, 
a nucleic acid, an antioxidant agent, a chemotherapeutic agent, a biological tissue and any 
combination thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said analyte from a group comprising an organic 
analyte and an inorganic analyte. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said inorganic analyte from a group comprising 
molecular oxygen, oxygen-containing radicals and combinations thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of detecting oxygen-containing radicals “ad hoc” generated, for 
assessing the anti-oxidant properties of the sample. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said paramagnetic core as a metal ion, a metal 
complex, oxides of a metal ion, oxides of a transition metal, mixed oxides of a transition 
metal and their mixtures. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said paramagnetic core from a group comprising 
metal complexes, aggregates of metal complexes, polymer-bound metal complexes, stable 
organic radicals and any combination thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said metal ion from a group comprising an ion of 
nickel, iron, manganese, copper, gadolinium, europium and mixtures thereof. 
It is another object of the present invention to disclose the method as defined above, based on 
a competition assay for assessing redox characteristics, comprising steps of detecting 
differences in Paramagnetic Relaxation Enhancement (PRE) properties induced by a change 
in at least one redox characteristic of said FPP, using an applied magnetic field. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said redox characteristic from a group comprising 
lipid peroxidation, lipid peroxidation followed by a change in membrane permeability, redox 
potential of metal ions, formation and cleavage of disulfide bonds, oxidation state, 
antioxidant activity and any combination thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of providing said FPP as a liposome loaded with a plurality of 
paramagnetic payloads. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of applying a magnetic field, thereby enhancing a change in the 
permeability of said liposome so as to affect a nuclear relaxation property of said sample. 
It is another object of the present invention to disclose the method as defined above, further 
comprising steps of applying a magnetic field, thereby enhancing a change in at least one of 
cleavage or formation of disulfide bonds of said moiety so as to affect a nuclear relaxation 
property of said sample. 
It is another object of the present invention to disclose the method as defined above, further 
comprising steps of applying a magnetic field, thereby affecting at least one property of said 
FPP selected from a group comprising concentration, lipid peroxidation, membrane 
permeability, redox potential, formation and cleavage of disulfide bonds, oxidation state, 
redox potential, activation state, binding affinity, and any combination thereof, so as to 
induce a change in a nuclear relaxation property of said sample. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of conjugating said liposome with a site-specific ligand. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of conjugating said liposome with a biotin activated molecule. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of providing said FPP as a biotinylated liposome. 
It is an object of the present invention to disclose a method for detection of a biomarker in a 
sample whose main component is water, comprising steps of:  
 a. obtaining a sample whose main component is water; 
 b. providing liposomes loaded with a plurality of paramagnetic agents, said liposomes 
are conjugated with a site specific moiety configured to interact with said biomarker 
in said sample; 
 c. contacting said liposomes with said sample under conditions that allow the 
interaction between the site specific moiety and said biomarker; 
 d. exposing said sample to an applied magnetic field; and, 
 e. measuring a change in a nuclear relaxation property of said sample caused by said 
interaction between the liposomes and said biomarker in the applied magnetic field;  
wherein a change in T.sub.1 nuclear relaxation property is correlated to the presence 
of said biomarker in said sample.  
It is another object of the present invention to disclose the method as defined above, 
comprising additional steps of:  
 a. providing biotinylated liposomes; said liposomes loaded with a plurality of 
paramagnetic agents; 
 b. providing biotinylayed ligands, said ligands configured to interact with said 
biomarker; 
 c. providing activated avidin molecules; 
 d. contacting said biotinylated liposomes, said biotinylayed ligands and said activated 
avidin molecules with said sample so as to enable avidin-biotin interaction, thereby 
forming complexes comprising said liposomes, said ligand and said biomarker; such 
that said complexes are specific to said biomarker; and, 
 e. measuring a change in a nuclear relaxation property of said sample caused by said 
complex formation in the applied magnetic field;  
wherein a change in T.sub.1 nuclear relaxation property is correlated to the presence 
of said biomarker in said sample.  
It is an object of the present invention to disclose a system for detecting a target biochemical 
molecular species or at least one property correlated with the occurrence of said biochemical 
molecular species in a sample whose main component is water, comprising;  
 a. a magnetic resonance device (MRD) configured to measure a change in nuclear 
relaxation property of said sample; and, 
 b. a plurality of Functionalized Paramagnetic Particles (FPP) said FPP comprising a 
paramagnetic core and a moiety configured to interact with said target biochemical 
molecular species or with molecules collectively reporting on a property of said target 
biochemical molecular species;  
wherein a change in T.sub.1 nuclear relaxation property of water protons in said 
sample measured by said MRD is correlated to the presence of said target biochemical 
molecular species and/or to the at least one property correlated with the occurrence of 
said biochemical molecular species in said sample, further wherein said FPP 
comprises a non ferrous oxide paramagnetic core.  
It is another object of the present invention to disclose the system as defined above, further 
comprises means for detecting said target biochemical molecular species and/or 
characterizing at least one property correlated with the occurrence of said biochemical 
molecular species in vitro. 
It is another object of the present invention to disclose the system as defined above, wherein 
said FPP is formed as a single molecule, a multimeric system, a micro-sized vesicle or 
particle, a nano-sized vesicle or particle, a liposome, a probe and any combination thereof. 
It is another object of the present invention to disclose the system as defined above, wherein 
said sample is selected from a group consisting of a liquid, a gas, a slurry, a liquid containing 
particulates, a gas containing particulates, a gel, a sol, a suspension, a solution, a dispersion, a 
colloid, a mixture, an emulsion, an aerosol, a liquid containing solid objects, a gas containing 
solid objects, and any combination thereof. 
It is another object of the present invention to disclose the system as defined above, wherein 
said sample is further selected from a group comprising a biological fluid, a biological tissue, 
a tissue extract, an industrial fluid, food sample, a beverage, wine, water, potable water, 
sewage, irrigation water, sea water, river water, lake water, industrial effluent, farm effluent, 
effluent from human habitation, road runoff, cleaning fluid, a gas sample or any combination 
thereof. 
It is another object of the present invention to disclose the system as defined above, wherein 
said biological fluid is selected from a group comprising urine, blood, lymph, plasma, 
cerebrospinal fluid, saliva, amniotic fluid, bile and tears. 
It is another object of the present invention to disclose the system as defined above, wherein 
said sample is provided within a production process. 
It is another object of the present invention to disclose the system as defined above, wherein 
said production process is in an industrial area, said industrial area is a member of a group 
consisting of the pharmaceuticals, food production, beverage production, chemical refining, 
chemical processing, medical products, biological products, metal casting, metal refining, 
desalination, fluid purification, and sewage processing. 
It is another object of the present invention to disclose the system as defined above, wherein 
said property is selected from a group comprising concentration, permeability, oxidation 
state, redox characteristic (reduction-oxidation state), activation state and any combination 
thereof. 
It is another object of the present invention to disclose the system as defined above, wherein 
said magnetic resonance device (MRD) is configured to enhance the change in a 
paramagnetic nuclear relaxation property of said sample upon comparing relaxation rates at 
two different magnetic fields. 
It is another object of the present invention to disclose the system as defined above, wherein 
said magnetic resonance device (MRD) is a portable NMR or MRI measuring means. 
It is another object of the present invention to disclose the system as defined above, wherein 
said magnetic resonance device (MRD) consists of magnets housed within a cage. 
It is another object of the present invention to disclose the system as defined above, wherein 
said magnetic resonance device (MRD) is a self-fastening cage type of a magnetic resonance 
device (300). 
It is another object of the present invention to disclose in a self-fastening cage of a magnetic 
resonance device (MRD) (300), a system as defined above wherein said self-fastening cage 
type MRD additionally characterized by an outside shell comprising at least three flexi-
jointed superimposed walls (1). 
It is another object of the present invention to disclose n a self-fastening cage type MRD 
(300), a system as defined above further comprises a MRD characterized by an outside shell; 
said outside shell comprising at least three flexi-jointed superimposed walls (1) disposed in a 
predetermined clockwise or counterclockwise arrangement; said MRD comprising:  
 a. at least six side-magnets (2) arranged in two equal groups being in a face-to-face 
orientation in a magnetic connection with said outside shell, increasing the overall 
strength of the magnetic field provided in said cage; 
 b. at least two pole-magnet pieces (3), arranged in a face-to-face orientation in 
between said side-magnets (2); 
 c. at least two main-magnets (4), located on said pole-pieces (3), arranged in a face-
to-face orientation, generating the static magnetic field therein said cage; and, 
 d. shimming mechanism, said mechanism is selected from a group consisting of an 
array of active shim coils, passive shimming elements or a combination thereof;  
wherein at least a portion of said side-magnets (2) are superconductors or 
ferromagnets.  
It is another object of the present invention to disclose the system as defined above, wherein 
said MRD is configured to produce high contrast high resolution images of said sample. 
It is another object of the present invention to disclose the system as defined above, wherein 
said magnetic resonance device comprising:  
 a. an envelope for least partially confining said sample; 
 b. a plurality of magnets located at least partially around said envelope, said plurality 
of magnets comprising:  
o i. a least one first magnet configured to provide a high magnetic field for 
generating multiple time-resolved one or more first images at high resolution 
of at least a portion of said sample; and 
o ii. a least one second magnet configured to provide a low magnetic field for 
generating multiple time-resolved one or more second images at high contrast 
of at least portion of same said sample; wherein at least one image of said first 
images and at least one image of said second images being generated in a time 
no greater than approximately the time between two first images; and, 
 c. a CPU to process said images comprising a computer readable medium containing 
instructions for generating at least one third image superimposing at least one image 
of said first images with at least one image of said second images, whereby a high 
contrast, high resolution real time continues image of said sample is obtained. 
It is another object of the present invention to disclose the system as defined above, wherein 
said at least one first magnet is of 2 Tesla and lower. 
It is another object of the present invention to disclose the system as defined above, wherein 
said at least one first magnet is of 2 Tesla and higher. 
It is another object of the present invention to disclose the system as defined above, wherein 
said at least one first magnet is selected from a group consisting of permanent magnets, 
electromagnets, superconducting magnets, and any combination thereof. 
It is another object of the present invention to disclose the system as defined above, wherein 
said at least one second magnet is of 2 Tesla and lower. 
It is another object of the present invention to disclose the system as defined above, wherein 
said at least one second magnet is of 2 Tesla and higher. 
It is another object of the present invention to disclose the system as defined above, wherein 
said at least one second magnet is selected from a group consisting of permanent magnets, 
electromagnets, superconducting magnets, and any combination thereof. 
It is another object of the present invention to disclose the system as defined above, wherein 
said magnetic resonance device (MRD) is configured to generate a magnetic resonance signal 
in the range of about 0.1 Tesla and about 10 Tesla. 
It is another object of the present invention to disclose the system as defined above, wherein 
said magnetic resonance device (MRD) is configured to generate a magnetic resonance signal 
in the range of 2 Tesla and lower. 
It is another object of the present invention to disclose the system as defined above, wherein 
said magnetic resonance device (MRD) is configured to generate a magnetic resonance signal 
in the range of 2 Tesla and higher. 
It is another object of the present invention to disclose the system as defined above, wherein 
said magnetic resonance device (MRD) is configured to generate a magnetic resonance 
frequency in the range of about 5 MHz to about 40 MHz. 
It is another object of the present invention to disclose the system as defined above, wherein 
said magnets are selected from a group consisting of permanent magnets, electromagnets, 
superconducting magnets, and any combination thereof. 
It is another object of the present invention to disclose the system as defined above, wherein 
said moiety is selected from a group comprising antibodies, antibody fragments, monoclonal 
antibody, receptors, ligands, macromolecules, peptides, hormones, fatty acids, lipids, receptor 
agonists and antagonists, amino acids, sugars, lectins, albumins, polycarbon molecules, 
glycoproteins, nucleic acids, pegylated molecules, liposomes, chelators, cells, viruses, 
chemotherapeutic agents and any combination thereof. 
It is another object of the present invention to disclose the system as defined above, wherein 
said target biochemical molecular species is selected from a group comprising a biological 
molecule, a chemical molecule, an analyte, a contaminant, a particle, a pathogen or any 
combination thereof. 
It is another object of the present invention to disclose the system as defined above, wherein 
said target biochemical molecular species is selected from a group comprising a protein, a 
pathogen, a prion, a virus, a bacteria, a contaminant, a pathological isoform, a biomarker, an 
allergen, a neurotransmitter, an antigenic determinant, an epitope, a cell marker, cell 
membrane marker or epitope, a membrane marker, an enzyme, a chemical molecule, an 
analyte, a receptor, a ligand, a macromolecule, a peptide, a hormone, a fatty acid, a lipid, a 
receptor agonist and antagonist, an amino acid, a sugar, a glycoprotein, a nucleic acid, an 
antioxidant agent, a chemotherapeutic agent, a biological tissue and any combination thereof. 
It is another object of the present invention to disclose the system as defined above, wherein 
said analyte is selected from a group comprising an organic analyte and an inorganic analyte. 
It is another object of the present invention to disclose the system as defined above, wherein 
said inorganic analyte is selected from a group comprising molecular oxygen, oxygen-
containing radicals and combinations thereof. 
It is another object of the present invention to disclose the system as defined above, wherein 
said oxygen-containing radicals are “ad hoc” generated radicals, for assessing the anti-
oxidant properties of the sample. 
It is another object of the present invention to disclose the system as defined above, wherein 
said paramagnetic core is selected from a group comprising a metal ion, a metal complex, 
oxides of a metal ion, oxides of a transition metal, mixed oxides of a transition metal and 
their mixtures. 
It is another object of the present invention to disclose the system as defined above, wherein 
said metal ion is selected from a group comprising an ion of nickel, iron, manganese, copper, 
gadolinium, europium and mixtures thereof. 
It is another object of the present invention to disclose the system as defined above, wherein 
said redox characteristic is selected from a group comprising lipid peroxidation, lipid 
peroxidation followed by a change in membrane permeability, redox potential of metal ions, 
formation and cleavage of disulfide bonds, oxidation state, antioxidant activity and any 
combination thereof. 
It is another object of the present invention to disclose the system as defined above, wherein 
said FPP is a liposome loaded with a plurality of paramagnetic payloads. 
It is another object of the present invention to disclose the system as defined above, 
comprising means for enhancing a change in the permeability of said liposome so as to affect 
a nuclear relaxation property of said sample. 
It is another object of the present invention to disclose the system as defined above, wherein 
said system is adapted to detect a change in at least one of cleavage or formation of disulfide 
bonds of said moiety so as to affect a nuclear relaxation property of said sample. 
It is another object of the present invention to disclose the system as defined above, wherein 
said property correlated with the occurrence of said biochemical molecular species is selected 
from a group comprising concentration, lipid peroxidation, membrane permeability, redox 
potential, formation and cleavage of disulfide bonds, oxidation state, redox potential, 
activation state, binding affinity, and any combination thereof. 
It is another object of the present invention to disclose the system as defined above, wherein 
said liposome is conjugated with a site-specific ligand. 
It is another object of the present invention to disclose the system as defined above, wherein 
said liposome is conjugated with a biotin activated molecule. 
It is another object of the present invention to disclose the system as defined above, wherein 
said FPP is a biotinylated liposome. 
It is an object of the present invention to disclose a system for detection of a biomarker in a 
sample, whose main component is water, comprising:  
 a. a sample whose main component is water; 
 b. liposomes loaded with a plurality of paramagnetic agents, said liposomes are 
conjugated with a site specific moiety configured to interact with said biomarker in 
said sample; 
 c. a magnetic resonance device (MRD) configured to measure a change in a nuclear 
relaxation property of a sample whose main component is water removed from said 
production batch or continuous flow of said FBW or biological fluid;  
wherein a change in T.sub.1 nuclear relaxation property of the water protons in said 
sample is correlated to the presence of said biomarker in said sample.  
It is an object of the present invention to disclose the use of Functionalized Paramagnetic 
Particles (FPP) to detect the presence or at least one other characteristic of a target 
biochemical molecular species within a sample whose main component is water, said FPP 
comprising a paramagnetic core and a moiety configured to interact with said target 
biochemical molecular species or with molecules collectively reporting on a property of said 
target biochemical molecular species; wherein a change in T.sub.1 nuclear relaxation 
property of water protons within said sample measured by a generated applied magnetic field 
is correlated to the presence or at least one other characteristic of said target biochemical 
molecular species in said sample. 
It is an object of the present invention to disclose the use as defined above further adapted to 
detect at least one property correlated with the occurrence of said biochemical molecular 
species in said sample. 
It is an object of the present invention to disclose a method of establishing the redox 
properties of a production batch or continuous flow of a Foodstuff, Beverage or Wine (FBW) 
or of a biological fluid, comprising the steps of:  
 a. obtaining a sample removed from said production batch or continuous flow of said 
FBW or from said biological fluid; 
 b. providing Functionalized Paramagnetic Particles (FPP) configured to change their 
redox property upon interaction with dissolved molecular oxygen or “ad hoc” 
generated radicals of said removed sample; 
 c. contacting said FPP with said removed sample; 
 d. exposing said removed sample to an applied magnetic field; and, 
 e. measuring a change in a nuclear relaxation property of said removed sample caused 
by said change in the redox properties of said FPP in the applied magnetic field;  
wherein a change in T.sub.1 nuclear relaxation property is correlated with the 
presence and/or concentration of said molecular oxygen or of the “ad hoc” generated 
radicals of said removed sample, thereby establishing the redox properties of said 
production batch or continuous flow of said FBW or of said biological fluid.  
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of providing said FPP conjugated with at least one moiety 
configured to interact with dissolved molecular oxygen or with “ad hoc” generated radicals. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said moiety from a group comprising a lipid, a fatty 
acid, an amino acid, a peptide, a protein, a molecule containing at least one disulfide bond, a 
liposome and any combination thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of measuring a change in a nuclear relaxation property of said 
sample caused by a change in the antioxidant activity of said removed sample in the applied 
magnetic field. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of measuring a difference in Paramagnetic Relaxation 
Enhancement (PRE) property of said removed sample caused by said interaction of said FPP 
with said dissolved molecular oxygen or with said “ad hoc” generated radicals. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of contacting said removed sample with FPP configured to 
form a liposome structure, said FPP comprising a paramagnetic core and a fatty acid moiety, 
wherein peroxidation of said fatty acid moiety substantially changes the permeability of said 
liposome. 
It is an object of the present invention to disclose the method as defined above, comprising an 
additional step of measuring a change in a nuclear relaxation property of said removed 
sample based on competition for molecular oxygen consumption. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of providing said FPP comprising a paramagnetic core selected 
from a group comprising a metal ion, a metal complex, oxides of a metal ion, oxides of a 
transition metal, mixed oxides of a transition metal and their mixtures. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said metal ion from a group comprising an ion of 
nickel, iron, manganese, copper, gadolinium, dysprosium, europium and mixtures thereof. 
It is another object of the present invention to disclose the method as defined above, 
comprising an additional step of selecting said biological fluid from a group comprising 
urine, blood, lymph, plasma, cerebrospinal fluid, saliva, amniotic fluid, bile and tears. 
It is an object of the present invention to disclose a system for establishing the redox 
properties of a production batch or continuous flow of a Foodstuff, Beverage, Wine (FBW) or 
of a biological fluid, comprising:  
 a. a magnetic resonance device (MRD) configured to measure a change in a nuclear 
relaxation property of a sample removed from said production batch or continuous 
flow of said FBW or of said biological fluid; and, 
 b. a plurality of Functionalized Paramagnetic Particles (FPP) configured to be in 
contact with said removed sample, said plurality of FPP are further configured to 
change at least one of their redox properties upon interaction with dissolved molecular 
oxygen or with “ad hoc” generated radicals of said removed sample;  
wherein a change in T.sub.1 nuclear relaxation property measured by said MRD is 
correlated to the presence or concentration of dissolved molecular oxygen or “ad hoc” 
generated radicals of said removed sample, thereby the redox properties of said 
production batch or continuous flow of said FBW or of said biological fluid are 
established.  
It is another object of the present invention to disclose the system as defined above, wherein 
said biological fluid is selected from a group comprising urine, blood, lymph, plasma, 
cerebrospinal fluid, saliva, amniotic fluid, bile and tears. 
It is another object of the present invention to disclose a system for establishing the 
portability of a production batch or continuous flow of a flowable Foodstuff, Beverage or 
Wine (FBW), comprising:  
 a. a magnetic resonance device (MRD) configured to measure a change in nuclear 
relaxation property of a sample removed from said production batch or continuous 
flow of said flowable FBW; and, 
 b. a plurality of functionalized paramagnetic particles (FPP) configured to be in 
contact with said sample, said plurality of FPP are further configured to change their 
redox/oxidative properties upon interaction with dissolved molecular oxygen or “ad 
hoc” generated radicals of said removed sample;  
wherein a change in T.sub.1 nuclear relaxation property measured by said MRD 
correlates with dissolved molecular oxygen or “ad hoc” generated radicals 
concentration of said FBW sample, thereby establishing the potability of said 
production batch or continuous flow of said flowable FBW.  
It is another object of the present invention to disclose the system as defined above, wherein a 
concentration value lower than about 6 ml of dissolved oxygen per liter of said removed 
sample is indicative of the potability of said production batch or continuous flow of said 
FBW. 
It is another object of the present invention to disclose the system as defined above, wherein a 
value lower than X ml of oxygen per liter is correlated to >7 of the 9 point hedonic scale. 
It is another object of the present invention to disclose the system as defined above, wherein a 
value lower than X ml of oxygen per liter is correlated to >y of the hybrid scale. 
It is another object of the present invention to disclose the system as defined above, wherein a 
value lower than X ml of oxygen per liter is correlated to >y of the self-adjusting scale. 
BRIEF DESCRIPTION OF THE DRAWINGS 
In order to understand the invention and to see how it may be implemented in practice, 
several embodiments will now be described, by way of non-limiting example only, with 
reference to the accompanying drawing, in which 
FIG. 1: is a schematic illustration of one embodiment of the system for assessment of cell 
epitopes, disclosed in the present invention; 
FIG. 2: is a schematic illustration of a further embodiment of the system for assessment of 
cell epitopes, disclosed in the present invention; 
FIG. 3: is a schematic diagram illustrating steps for assessment of cell receptors according to 
an embodiment of the present invention; 
FIG. 4: is a graphic representation of relaxivity results at different proton larmor frequencies; 
FIG. 5: is a graphic representation showing relaxation rate by Mn(II) ion concentration; 
FIG. 6: is a schematic illustration of a process for preparation of paramagnetic liposomes 
according to an embodiment of the present invention; 
FIG. 7: schematically presents a partial sectional top and out of scale view, with respect to an 
axial plane of the MRD (300) wherein the shape of a square parallelepiped is provided, 
having four cage walls (1), four side magnets (2); and a pole-piece (3); said cage walls and 
side-magnets are essentially interconnected in a superimposed manner such that a self-
fastening cage is obtained; 
FIG. 8: schematically presents an entire perspective view of the of the 3D MRD (300), 
having two cage walls (1), eight side magnets (2); two pole-pieces (3); two main magnet (4) 
and eight square corner-magnets (5) and four cylinder corner-magnets located inside the pole-
pieces; all of them are arranged in two equal groups face-to-face orientation; and, 
FIG. 9: schematically illustrates an embodiment with a high contrast, high resolution 
magnetic resonance device. 
DETAILED DESCRIPTION OF THE INVENTION 
The following description is provided, alongside all chapters of the present invention, so as to 
enable any person skilled in the art to make use of said invention and sets forth the best 
modes contemplated by the inventor of carrying out this invention. Various modifications, 
however, will remain apparent to those skilled in the art, since the generic principles of the 
present invention have been defined specifically to provide a method for detection of a 
biochemical molecular species in a sample and a system thereof. 
Assessment of markers can be pursued by a number of techniques and NMR/MRI is one of 
them. The detection of a biomarker implies the use of a probe that binds or is responsive to 
the given biomarker. The probe acts as reporter in the selected NMR/MRI modality. A 
modality endowed with high sensitivity which is represented by 1H-Relaxometry as the 
measured signal arising from the “bulk” water solvent, is provided by the present invention. 
By this approach one measures the effect of the responsiveness of the probe on specific 
properties of the water 1H resonance in the presence of the biomarker of interest. T1, T2 and 
T2* are the parameters that may be taken in consideration in the herein provided 
1H-
relaxometric assay. 
According to one embodiment, the present invention provides a method for detecting a target 
biochemical molecular species in a sample, especially a sample whose main component is 
water, comprising; (a) obtaining a sample; (b) providing Functionalized Paramagnetic 
Particles (FPP) configured to interact with said target biochemical molecular species, each 
FPP comprising a paramagnetic core and a moiety configured to interact with said target 
biochemical molecule or a set of biochemical molecules collectively defining a property of 
the specimen; (c) contacting said FPP with said sample under conditions that allow the 
interaction between said FPP and said biochemical molecular species; (d) exposing said 
sample to an applied magnetic field; and, (e) measuring a change in a nuclear relaxation 
property of water protons of said sample caused by said interaction between said FPP and 
said biochemical molecular species, in the applied magnetic field. In a core aspect of the 
invention, a change in T.sub.1 nuclear relaxation property of water protons is correlated to 
the presence of said target biochemical molecular species in said sample and/or to at least one 
property associated with the occurrence of said biochemical molecular species in said sample. 
In a further embodiment of the invention, the FPP comprises a particle made of a non ferrous 
oxide paramagnetic core. 
In a further embodiment, the present invention provides A method for detecting a target 
biochemical molecular species or at least one property correlated with the occurrence of said 
biochemical molecular species in a sample whose main component is water, comprising; (a) 
obtaining a sample whose main component is water; (b) providing Functionalized 
Paramagnetic Particles (FPP) comprising a paramagnetic core and a moiety configured to 
interact with said target biochemical molecular species or with molecules collectively 
reporting on a property of said target biochemical molecular species; (c) contacting said FPP 
with said sample; (d) exposing said sample to an applied magnetic field; and, (e) measuring a 
change in a nuclear relaxation property of said sample, caused by said interaction between 
said FPP and said biochemical molecular species or said molecules collectively reporting on 
a property of said target biochemical molecular species; in the applied magnetic field; and, (f) 
correlating said change to the presence of said biochemical molecular species in said sample 
or to at least one property correlated with the occurrence of said biochemical molecular 
species in said sample; wherein a change in T.sub.1 nuclear relaxation property of the water 
protons in said sample is correlated to the presence of said target biochemical molecular 
species or to at least one property correlated with the occurrence of said biochemical 
molecular species in said sample, further wherein said FPP comprises a non ferrous oxide 
paramagnetic core. 
It is herein disclosed that according to a main embodiment, the present invention uniquely 
combines NMR relaxometer technology, preferably a portable NMR device, with an 
amplification procedure for the quantification of a biomarker or biochemical molecule or 
biochemical molecular species of interest. The present invention provides a novel 
relaxometric assay based on appropriately designed functionalized paramagnetic particles 
(FPP), preferably liposomes, containing a paramagnetic core or paramagnetic species and a 
moiety/moieties, which is/are specifically designed to interact and/or be responsive to the 
target biomarker or biochemical molecular species or analyte of interest. 
The use of paramagnetic species allows determining different concentrations of i.e. a 
biomarker or analyte of interest within the tested sample, thus affecting for example the 
assessment between healthy and diseased tissues. Gadolinium (Gd)-based contrast agents are 
the most used systems. The development of new Gd-based or other metal ion contrast agents 
with high relaxation enhancement ability and targeting capability is a further aspect of the 
present invention. It is also within the scope of the present invention to set-up innovative 
molecular magnetic resonance protocols. These protocols are capable of detecting epitopes 
that are present at very low concentrations (typically in the 50-100 nmol/L range) and 
therefore it is necessary to design proper means and methods to amplify the response upon 
recognition of the target molecule of interest. 
According to one aspect, the present invention provides a magnetic resonance-relaxometric 
assay and system adapted to measure small volume of samples. 
According to certain aspects of the present invention, automated systems (i.e. a processor) 
and procedures are herein provided configured to determining a change in nuclear relaxation 
properties of a sample containing a target biochemical molecule or biochemical molecular 
species of interest. These automated systems and procedures are further capable of 
correlating the measured change in the nuclear relaxation enhancement with the 
quantification of the target biochemical molecule or biochemical molecular species or an 
overall property of interest within said sample. 
It is further within the scope of the present invention to disclose means and methods for 
performing quality control of the produced functionalized paramagnetic particles and the T1 
measurements that reports on a specific target biomarker or epitope of interest. 
It is further within the scope of the present invention to disclose means and methods for 
detecting at least one property correlated with the occurrence of a biochemical molecular 
species in a sample. 
In a further embodiment of the invention the method as disclosed herein further comprises 
steps of analyzing at least one characteristic or property of the target molecular species 
selected from a group comprising concentration, permeability, oxidation state, redox 
characteristic (reduction-oxidation state), activation state and any combination thereof. 
As used herein the term ‘plurality’ applies hereinafter to any integer greater than or equal to 
one. 
The term ‘about’ denotes ±25% of the defined amount or measure or value. 
The term ‘biochemical molecule’ as used herein refers to any chemical or biological 
molecule. Examples of chemical or biological molecules included within the scope of the 
present invention may comprise, but are not limited to: a protein, a pathogen, a prion, a virus, 
a bacteria, a contaminant, a pathological isoform, a biomarker, an allergen, a 
neurotransmitter, an antigenic determinant, an epitope, a cell marker, cell membrane marker 
or epitope, a membrane marker, an enzyme, a chemical molecule, an analyte, a receptor, a 
ligand, a macromolecule, a peptide, a hormone, a fatty acid, a lipid, a receptor agonist and 
antagonist, an amino acid, a sugar, a glycoprotein, a nucleic acid, an antioxidant agent, a 
chemotherapeutic agent, a biological tissue and any combination thereof. 
The term ‘biochemical molecular species’ as used herein refers to a biological or chemical 
molecule as defined above or a set of biochemical molecules, collectively defining a property 
of a specimen or to one or more biochemical molecules collectively reporting on a given 
property. It is within the disclosure of the present invention that the term ‘biochemical 
molecular species’ refers to biochemical molecules that are substantially similar in their 
chemical and/or biological properties and their identification and quantification are of 
interest. In other embodiments, the term ‘biochemical molecular species’ can be applied to an 
ensemble or family of chemically or biologically identical molecular entities that can explore 
the same set of chemical or biological characteristics. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of selecting the analyte from a group comprising an organic analyte and an 
inorganic analyte. 
The term ‘particle’ refers hereinafter to any form comprising, but not limited to, a single 
molecule, a multimeric molecule or system, a macromolecule, a monomer, an oligomer, a 
polymer, a vesicle, a nano or micro sized vesicle, a liposome, a probe, a cell, a yeast cell or 
any combination thereof. 
The term ‘Functionalized Paramagnetic Particle’ or ‘FPP’ refers hereinafter to a particle or 
probe containing a paramagnetic entity or agent or core and a moiety that is adapted to 
interact with a target biochemical molecular species or biomarker of interest. 
In a preferred embodiment of the invention, the paramagnetic entity, agent, or core 
constitutes a non ferrous oxide metal ion. According to certain embodiments, the 
paramagnetic entity, agent, or core comprise a metal ion, including oxides of a metal ion, 
oxides of a transition metal, mixed oxides of a transition metal and their mixtures. More 
specifically, the metal ion may be selected from a group comprising an ion of nickel, 
manganese, copper, gadolinium, dysprosium, europium and mixtures thereof. 
In another embodiment of the invention, the FPP may include a moiety or residue adapted to 
specifically interact with a target biochemical molecular species or biomarker of interest. 
Such a moiety or residue may comprise a receptor, ligand or any compound, such as a 
biomolecule or a small molecule, an antibody or an antigen-binding fragment that binds 
specifically to a selected target molecule or analyte. In specific embodiments, a moiety or 
residue may comprise a macromolecule, a peptide, a hormone, a fatty acid, a lipid, a receptor 
agonist and/or antagonist, an amino acid, a sugar, lectins, albumins, polycarbon molecules, 
glycoproteins, nucleic acids, pegylated molecules, liposomes, chelators, cells, viruses, 
chemotherapeutic agents, biotin, streptavidin and any combination thereof. In preferred 
embodiments of the invention, such functional moieties or residues as herein described are 
configured to confer the FPP with molecular specificity, such that the change in the measured 
T.sub.1 nuclear relaxation property correlates with the presence and/or concentration of the 
target biochemical molecular species or biomarker of interest or to a collective property of 
the specimen. 
The term ‘paramagnetic core’ used herein refers hereinafter to a paramagnetic species or 
paramagnetic payload or paramagnetic entity or paramagnetic agent that may include a metal 
ion, a metal complex, oxides of a metal ion, oxides of a transition metal, mixed oxides of a 
transition metal, metal complexes, aggregates of metal complexes, polymer-bound metal 
complexes, stable organic radicals and their mixtures. The metal ion may be selected from a 
group comprising an ion of nickel, iron, manganese, copper, gadolinium, europium and 
mixtures thereof. 
The term ‘nuclear relaxation property’ refers hereinafter to the relaxation of water protons. 
The effect is a change in magnetic resonance signal, which is measured as a shortening of the 
longitudinal (T1, spin-lattice) and transverse (T2, spin-spin) relaxation times. In one 
embodiment, the capacity of the paramagnetic species to decrease T1 and T2 is respectively 
defined as the transverse and the longitudinal relaxivities. It is herein acknowledged that T1 
values are longer at higher field strengths. Furthermore, the T1 parameter is not affected by 
internal magnetic field gradients or by differences in fluid diffusivity. Moreover, instrument 
artifacts influence T1 measurements to a much lesser degree than T2 measurements. 
Thus, in one aspect, the system and method of the present invention is directed to detecting a 
biochemical molecule(s) or biochemical molecular species in a sample by measuring a 
change in the T1 nuclear relaxation property of said sample, operated by an interaction 
between Functionalized Paramagnetic Particles (FPP) and the biochemical molecular species, 
in the applied magnetic field. The aforementioned change in T1 nuclear relaxation property is 
correlated to the presence of said target biochemical molecular species in said sample. 
In another aspect, the invention is directed towards novel combinations of T1 and T2 
measurements, for example, to detect the presence and/or concentration of a biochemical 
molecular species or analyte of interest in a sample. In one embodiment, these combinations 
of T1 and T2 measurements may provide synergistic effects with respect to detection and 
characterization of a target biochemical molecular species. 
The term ‘ad hoc generated radicals’ as used herein refers to atoms, molecules, or ions with 
unpaired electrons or an open shell configuration, generated for, or as a result of, a particular 
or special purpose or end presently under consideration. Because of the unpaired electrons, 
free radicals are highly chemically reactive. Free radicals may have positive, negative, or zero 
charge. 
According to specific embodiments, the term ‘ad hoc generated radicals’ relates to detecting 
generated oxygen-containing radicals using the means and methods as described inter alia for 
assessing the anti-oxidant properties of a sample of interest. 
The term ‘correlated to’ or ‘correlates with’ refers hereinafter to either a positive or negative 
dependence or connection or correspondence between two variables, parameters or sets of 
data, i.e. between the measured change in nuclear relaxation property of an analysed sample 
and presence or other characteristic of a target biochemical molecular species within said 
sample. 
The term ‘non ferrous oxide’ is used hereinafter to indicate metals other than iron and more 
particularly to oxides of ions that are not iron-based. 
The term ‘portable’ applies hereinafter to any hand held or wearable devices. The device can 
be carried or worn by the human body on a belt or in a pocket. 
The term ‘self-fastening’ refers hereinafter to a strong magnetic connection between the side-
magnets and the cage walls. The magnets' edges are attracted to each other such that a closed 
form is provided. The cage, magnetically attracted to the side-magnets, supports itself 
without need for another connection. 
The term ‘flexi-jointed’ refers hereinafter to the geometric arrangement of the cage walls 
wherein the joints of the walls are separated by an air gap, such that at least a portion of said 
walls is left free to move and thus, if dislocation of one of the walls occurs, it is able to re-
adjust so as to fit with adjacent (sometimes perpendicular) wall. The flexi-jointed walls form 
the cage in such a manner that at least one of its x, y or z dimensions is adjustable; hence a 
variation of the cage contour, size or shape, e.g., cross section is obtained. 
The term ‘superimposed’ refers hereinafter to the arrangement of the cage walls; each wall is 
placed over the other in an overlaying manner. 
The term ‘magnetic resonance device’ (MRD) applies hereinafter to any Magnetic Resonance 
Imaging (MRI) device, any Nuclear Magnetic Resonance (NMR) spectroscope, any Electron 
Spin Resonance (ESR) spectroscope, any Nuclear Quadrupole Resonance (NQR), any NMR 
relaxometer apparatus, or a portable NMR or MRI or any combination thereof. 
The term ‘tolerance’ refers hereinafter to the interval between the corner-magnets and the 
cage walls, enabling displacement of the walls. 
The term ‘adjust’ applies hereinafter to a change of the magnet's parameters before or after 
assembly, to optimize the magnetic field uniformity. 
The term ‘pole-piece’ applies hereinafter to an element of high permeability material used to 
shape the uniformity of the magnetic flux from a permanent magnet. 
The term ‘side-magnets’ applies hereinafter to permanent magnets arranged around the sides 
of pole-pieces. 
The term ‘sample imaging units’ applies hereinafter to a device adapted to provide a means 
of measuring the magnetic resonance of a sample within a uniform magnetic field. 
The term ‘fluid imaging units’ applies hereinafter to a device adapted to provide a means of 
measuring the magnetic resonance of a fluid sample within a uniform magnetic field. 
The term ‘switching rate’ applies hereinafter to the number of separated devices which are 
activated in a given time period. 
The term ‘stratificated device’ refers hereinafter to any MRD 300 which is characterized by 
more than two layers, forming more than two detecting volumes, e.g., in a top-and-bottom 
configuration and/or at least two adjacent feeding streams carrying a plurality of objects in 
said configuration. 
The term ‘residue’ or ‘residues’ as used herein refers to any particle or particulate specific to 
a selected biological or chemical agent. It is within the scope of the present invention that 
such a residue may include, but it is not limited to a biomarker, a DNA, a protein, a peptide 
or any other part of a selected biological or chemical agent, particularly a pathogen. 
The term ‘MRI contrast agents’ refers hereinafter in a non-limiting manner to a compound or 
other substance introduced to the anatomical or functional region being imaged in order to 
enhance the contrast of structures, due to difference in the apparent density of various organs 
and tissues. Contrast agents are used in medical imaging studies to make it easier to see the 
internal structures of the body. The addition of contrast agents in many cases improves 
sensitivity and/or specificity to improve tissue discrimination in MRI. MRI contrast agents 
are classified by the different changes in relaxation times after their injection. The most 
commonly used intravenous contrast agents are based on chelates of gadolinium. 
The term ‘rapidly’ refers herein to a time interval of less than 5 minutes. 
The term ‘nearly contemporaneously’ refers to a time interval less than the time interval 
between generation of successive first images. 
It is thus one embodiment of the present invention to provide, a method for detecting a target 
biochemical molecular species in a sample, comprising; (a) obtaining a sample; (b) providing 
Functionalized Paramagnetic Particles (FPP) configured to interact with said target 
biochemical molecular species of said sample, each FPP comprising a paramagnetic core and 
a moiety configured to interact with said target biochemical molecular species or a set of 
biomedical molecules collectively defining a property of the specimen; (c) contacting said 
FPP with said sample under conditions that allow the interaction between said FPP and said 
biochemical molecular species or molecules; (d) exposing said sample to an applied magnetic 
field; and, (e) measuring a change in a nuclear relaxation property of said sample caused by 
said interaction between said FPP and said biochemical molecular species or molecules, in 
the applied magnetic field; wherein a change in T.sub.1 nuclear relaxation property is 
correlated to the presence of said target biochemical molecular species in said sample, further 
wherein said FPP comprises a particle made of a non ferrous oxide paramagnetic core. 
It is a further embodiment of the present invention to provide a method for characterizing a 
target biochemical molecular species in a sample, comprising; (a) providing a sample; (b) 
providing Functionalized Paramagnetic Particles (FPP) adapted to interact with said target 
biochemical molecular species, each FPP comprising at least one paramagnetic core and at 
least one moiety that is adapted to interact with said target biochemical molecular species; (c) 
contacting said FPP with said sample under conditions that allow the interaction between said 
FPP and said target biochemical molecular species; (d) exposing said sample to an applied 
magnetic field; and, (e) measuring a change in a nuclear relaxation property of said sample 
caused by said interaction between said FPP and said target biochemical molecular species in 
the applied magnetic field; wherein a change in T.sub.1 nuclear relaxation property is 
correlated to at least one characteristic of said target biochemical molecular species in said 
sample, further wherein said FPP comprises a non ferrous oxide paramagnetic core or 
paramagnetic species. 
It is further within the scope of the present invention that the analyzed samples are either 
solid, liquid gas or a combination thereof. Especially, the analyzed sample may comprise a 
biological fluid, a biological tissue, a tissue extract, an industrial fluid, food sample, a 
beverage, wine, water and any combination thereof. 
More specifically, a biological fluid sample may derived, for example, of urine, blood, 
plasma, lymph, cerebrospinal fluid, saliva, amniotic fluid, bile and tears. 
It is also in the scope of the present invention to provide the method as defined above, further 
comprising steps of performing two or more measurements to determine the relaxation time 
of the sample, wherein the measurements are performed before and after at least one addition 
of said FPP. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of detecting said target biochemical molecular species and/or characterizing 
at least one property correlated with the occurrence of said biochemical molecular species in 
vitro. 
It is still in the scope of the present invention to provide the method as defined above, 
wherein said FPP are formed as a single molecule, a multimeric system, a micro-sized vesicle 
or particle, a nano-sized vesicle or particle, a liposome, a probe or any combination thereof. 
It is still in the scope of the present invention to provide the method as defined above, 
comprising an additional step of selecting said sample from a group consisting of a liquid, a 
gas, a slurry, a liquid containing particulates, a gas containing particulates, a gel, a sol, a 
suspension, a solution, a dispersion, a colloid, a mixture, an emulsion, an aerosol, a liquid 
containing solid objects, a gas containing solid objects, and any combination thereof. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of selecting said sample from a group comprising a biological fluid, a 
biological tissue, a tissue extract, an industrial fluid, food sample, a beverage, wine, water, 
potable water, sewage, irrigation water, sea water, river water, lake water, industrial effluent, 
farm effluent, effluent from human habitation, road runoff, cleaning fluid, a gas sample or 
any combination thereof. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of selecting said biological fluid from a group comprising urine, blood, 
plasma, lymph, cerebrospinal fluid, saliva, amniotic fluid, bile and tears. 
It is still in the scope of the present invention to provide the method as defined above, 
comprising an additional step of providing said sample within a production process. 
It is still in the scope of the present invention to provide the method as defined above, 
comprising an additional step of selecting said production process in an industrial area, said 
industrial area is a member of a group consisting of the pharmaceuticals, food production, 
beverage production, chemical refining, chemical processing, medical products, biological 
products, metal casting, metal refining, desalination, fluid purification, and sewage 
processing. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of analyzing at least one characteristic or property of said target molecular 
species selected from a group comprising concentration, permeability, oxidation state, redox 
characteristic (reduction-oxidation state), activation state and any combination thereof. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of applying a magnetic field, thereby enhancing a change in a paramagnetic 
nuclear relaxation property of said sample upon comparing relaxation rates at two different 
magnetic fields. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of measuring a change in a nuclear relaxation property of said sample using 
a portable NMR or MRI measuring means. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of measuring a change in a nuclear relaxation property of said sample using 
a magnetic resonance device (MRD) consisting of magnets housed within a cage. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of measuring a change in a nuclear relaxation property of said sample using 
a self-fastening cage type of a magnetic resonance device (MRD) (300). 
According to a further embodiment of the present invention, in a self-fastening cage of a 
magnetic resonance device (MRD) (300), a method as defined above further comprises steps 
of providing a homogeneous, stable and uniform magnetic field therein, further wherein said 
self-fastening cage type MRD additionally characterized by an outside shell comprising at 
least three flexi-jointed superimposed walls (1). 
According to a further embodiment of the present invention, in a self-fastening cage type 
MRD (300), a method as defined above further comprises steps of providing an MRD 
characterized by an outside shell; said outside shell comprising at least three flexi-jointed 
superimposed walls (1) disposed in a predetermined clockwise or counterclockwise 
arrangement; said MRD comprising: (a) at least six side-magnets (2) arranged in two equal 
groups being in a face-to-face orientation in a magnetic connection with said outside shell, 
increasing the overall strength of the magnetic field provided in said cage; (b) at least two 
pole-magnet pieces (3), arranged in a face-to-face orientation in between said side-magnets 
(2); (c) at least two main-magnets (4), located on said pole-pieces (3), arranged in a face-to-
face orientation, generating the static magnetic field therein said cage; and, (d) shimming 
mechanism, said mechanism is selected from a group consisting of an array of active shim 
coils, passive shimming elements or a combination thereof; wherein at least a portion of said 
side-magnets (2) are superconductors or ferromagnets. 
It is further in the scope of the present invention to provide a magnetic resonance device 
(MRD) comprising: a means of producing a large, uniform magnetic field around a sample, 
such as a large permanent magnet and shimming mechanism selected from active or passive 
shimming elements; a means of producing a magnetic field gradient around the sample; and a 
magnetic resonance sensing probe comprising an inductance coil and capacitor connected to a 
radio antenna. 
It is still in the scope of the present invention to provide the method as defined above, 
wherein said applied magnetic field comprises a magnetic resonance signal level in the range 
of about 0.1 Tesla and about 10 Tesla. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprises steps of applying a magnetic resonance frequency in the range of about 5 MHz to 
about 40 MHz. 
It is still in the scope of the present invention to provide the method as defined above, 
comprising an additional step of providing a magnetic resonance device adapted to producing 
high contrast high resolution images of said sample. 
It is still in the scope of the present invention to provide the method as defined above, 
comprising an additional step of providing a magnetic resonance device comprising: (a) an 
envelope for least partially confining said sample; (b) a plurality of magnets located at least 
partially around said envelope; and, (c) a CPU to process said images comprising a computer 
readable medium containing instructions for generating at least one third image 
superimposing at least one image of said first images with at least one image of said second 
images. In a specific embodiment, the plurality of magnets comprising: (a) a least one first 
magnet configured to provide a high magnetic field for generating multiple time-resolved one 
or more first images at high resolution of at least a portion of said sample; and (b) a least one 
second magnet configured to provide a low magnetic field for generating multiple time-
resolved one or more second images at high contrast of at least portion of same said sample; 
wherein at least one image of said first images and at least one image of said second images 
being generated in a time no greater than approximately the time between two first images. 
It is still in the scope of the present invention to provide the method as defined above, 
comprising additional steps of: (a) generating multiple time resolved one or more first images 
at high resolution of at least a portion of said sample; (b) generating multiple time resolved 
one or more second images at high contrast of at least portion of same said sample; and (c) 
superimposing at least one image of said first images with at least one image of said second 
images; whereby a high-contrast, high resolution real-time continuous image of said sample 
is obtained. 
It is still in the scope of the present invention to provide the method as defined above, 
comprising an additional step of selecting said at least one first magnet to be of 2 Tesla and 
lower. 
It is still in the scope of the present invention to provide the method as defined above, 
comprising an additional step of selecting said at least one first magnet to be of 2 Tesla and 
higher. 
It is still in the scope of the present invention to provide the method as defined above, 
comprising an additional step of selecting said at least one first magnet from a group 
consisting of permanent magnets, electromagnets, superconducting magnets, and any 
combination thereof. 
It is still in the scope of the present invention to provide the method as defined above, 
comprising an additional step of selecting said at least one second magnet to be of 2 Tesla 
and lower. 
It is still in the scope of the present invention to provide the method as defined above, 
comprising an additional step of selecting said at least one second magnet to be of 2 Tesla 
and higher. 
It is still in the scope of the present invention to provide the method as defined above, 
comprising an additional step of selecting said at least one second magnet from a group 
consisting of permanent magnets, electromagnets, superconducting magnets, and any 
combination thereof. 
It is still in the scope of the present invention to provide the method as defined above, 
comprising an additional step of selecting said magnets from a group consisting of permanent 
magnets, electromagnets, superconducting magnets, and any combination thereof. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of selecting said moiety from a group comprising antibodies, antibody 
fragments, monoclonal antibody, receptors, ligands, macromolecules, peptides, hormones, 
fatty acids, lipids, receptor agonists and antagonists, amino acids, sugars, lectins, albumins, 
polycarbon molecules, glycoproteins, nucleic acids, pegylated molecules, liposomes, 
chelators, cells, viruses, chemotherapeutic agents and any combination thereof. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of detecting and/or analysing a target molecular species selected from a 
group comprising a biological molecule, a chemical molecule, an analyte, a contaminant, a 
particle, a pathogen or any combination thereof. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of selecting said target biochemical molecular species from a group 
comprising a protein, a pathogen, a prion, a virus, a bacteria, a contaminant, a pathological 
isoform, a biomarker, an allergen, a neurotransmitter, an antigenic determinant, an epitope, a 
cell marker, cell membrane marker or epitope, a membrane marker, an enzyme, a chemical 
molecule, an analyte, a receptor, a ligand, a macromolecule, a peptide, a hormone, a fatty 
acid, a lipid, a receptor agonist and antagonist, an amino acid, a sugar, a glycoprotein, a 
nucleic acid, an antioxidant agent, a chemotherapeutic agent, a biological tissue and any 
combination thereof. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of selecting said analyte from a group comprising an organic analyte and an 
inorganic analyte. 
It is still in the scope of the present invention to provide the method as defined above, 
wherein said inorganic analyte is molecular oxygen or an oxygen-containing molecule or 
oxygen containing radicals and combinations thereof. 
It is still in the scope of the present invention to provide the method as defined above, 
comprising an additional step of detecting oxygen-containing radicals “ad hoc” generated, for 
assessing the anti-oxidant properties of the sample. 
It is still in the scope of the present invention to provide the method as defined above, 
wherein said paramagnetic core is a metal ion, oxides of a metal ion, oxides of a transition 
metal, mixed oxides of a transition metal and their mixtures. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of selecting said metal ion from a group comprising an ion (except for iron 
oxide) of nickel, manganese, copper, gadolinium, dysprosium, europium and mixtures 
thereof. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of selecting said paramagnetic core or species loaded in the FPP from a 
group comprising metal complexes, aggregated of metal complexes, polymer-bound metal 
complexes, stable organic radicals and mixtures thereof. 
It is still in the scope of the present invention to provide the method as defined above, based 
on a competition assay for assessing oxygen consumption or redox characteristics, 
comprising steps of detecting differences in Paramagnetic Relaxation Enhancement (PRE) 
properties induced by a change in at least one redox characteristic of said FPP, using an 
applied magnetic field. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprises steps of selecting said redox characteristic from a group comprising lipid 
peroxidation, lipid peroxidation followed by a change in membrane permeability, redox 
potential of metal ions, formation and cleavage of disulfide bonds, oxidation state, 
antioxidant activity and any combination thereof. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprises a step of providing said FPP as a liposome loaded with a plurality of paramagnetic 
cores or payloads. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of applying a magnetic field, thereby enhancing a change in the 
permeability of said liposome so as to affect a nuclear relaxation property of said sample. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of applying a magnetic field, thereby enhancing a change in at least one of 
cleavage or formation of disulfide bonds of said moiety so as to affect a nuclear relaxation 
property of said sample. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprising steps of applying a magnetic field, thereby affecting at least one property of said 
FPP selected from a group comprising concentration, lipid peroxidation, membrane 
permeability, redox potential, formation and cleavage of disulfide bonds, oxidation state, 
redox potential, activation state, binding affinity, and any combination thereof, so as to 
induce a change in a nuclear relaxation property of said sample. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprises steps of conjugating said liposome with a site-specific ligand. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprises steps of conjugating said liposome with a biotin activated molecule. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprises steps of providing said FPP as a biotinylated liposome. 
According to a further embodiment, the present invention provides a method for detection of 
a biomarker in a sample whose main component is water, comprising steps of: (a) obtaining a 
sample; (b) providing liposomes loaded with a plurality of paramagnetic agents, said 
liposomes are conjugated with a site specific moiety configured to interact with said 
biomarker in said sample; (c) contacting said liposomes with said sample under conditions 
that allow the interaction between the site specific moiety and said biomarker; (d) exposing 
said sample to an applied magnetic field; and, (e) measuring a change in a nuclear relaxation 
property of said sample caused by said interaction between the liposomes and said biomarker 
in the applied magnetic field; wherein a change in T.sub.1 nuclear relaxation property is 
correlated to the presence of said biomarker in said sample. 
It is still in the scope of the present invention to provide the method as defined above, further 
comprises the steps of: (a) providing biotinylated liposomes; said liposomes loaded with a 
plurality of paramagnetic agents; (b) providing biotinylayed ligands, said ligands configured 
to interact with said biomarker; (c) providing activated avidin molecules; (d) contacting said 
biotinylated liposomes, said biotinylayed ligands and said activated avidin molecules with 
said sample so as to enable avidin-biotin interaction, thereby forming complexes comprising 
said liposomes, said ligand and said biomarker; such that said complexes are specific to said 
biomarker; and, (e) measuring a change in a nuclear relaxation property of said sample 
caused by said complex formation in the applied magnetic field; wherein a change in T.sub.1 
nuclear relaxation property is correlated to the presence of said biomarker in said sample. 
In a further embodiment, the present invention provides a system for detecting a target 
biochemical molecular species or at least one property correlated with the occurrence of said 
biochemical molecular species in a sample, especially a sample whose main component is 
water, said system comprising; (a) a magnetic resonance device (MRD) configured to 
measure a change in nuclear relaxation property of said sample; and, (b) a plurality of 
Functionalized Paramagnetic Particles (FPP) configured to interact with said target 
biochemical molecular species of said sample, each of said FPP comprising a paramagnetic 
core and a moiety configured to interact with said target biochemical molecular species, or 
with molecules collectively reporting on a property of said target biochemical molecular 
species; wherein a change in T.sub.1 nuclear relaxation property measured by said MRD is 
correlated to the presence of said FPP and said biochemical molecular species and/or at least 
one property correlated with the occurrence of said biochemical molecular species in said 
sample, thereby detecting the presence of said target biochemical molecular species in said 
sample, further wherein said FPP comprises a non ferrous oxide paramagnetic core. 
In a further embodiment the present invention provides a use of Functionalized Paramagnetic 
Particles (FPP) configured to interact with a predetermined target biochemical molecular 
species or a biomarker within a sample, to detect the presence or at least one other 
characteristic of said target biochemical molecular species or biomarker, each of said FPP 
comprising a paramagnetic core and a moiety configured to interact with said target 
biochemical molecular species or with molecules collectively reporting on a property of said 
target biochemical molecular species; wherein a change in T.sub.1 nuclear relaxation 
property measured by a generated applied magnetic field is correlated to the presence or at 
least one other characteristic of said target biochemical molecular species in said sample. 
In a further embodiment, the present invention provides a method of establishing the redox 
potential of a production batch or continuous flow of a Foodstuff, Beverage or Wine (FBW), 
or of a biological fluid, comprising the steps of: (a) obtaining a sample removed from said 
production batch or continuous flow of said FBW or from a biological fluid; (b) providing 
Functionalized Paramagnetic Particles (FPP) configured to change their redox potential upon 
interaction with dissolved molecular oxygen or to active radicals “ad hoc” generated in said 
removed sample; (c) contacting said FPP with said removed sample; (d) exposing said 
removed sample to an applied magnetic field; and, (e) measuring a change in a nuclear 
relaxation property of said removed sample caused by said change in the redox potential or 
antioxidant properties of said FPP in the applied magnetic field; wherein a change in T.sub.1 
nuclear relaxation property is correlated with the concentration of said molecular oxygen or 
of radicals of said removed sample, thereby establishing the redox potential or the anti-
oxidant ability of said production batch or continuous flow of said FBW or of said biological 
fluid. 
It is also within the scope of the present invention to provide the method as described above, 
further comprising the step of providing said FPP conjugated with at least one moiety 
configured to interact with dissolved molecular oxygen on the “ad hoc” generated radicals. 
It is still within the scope of the present invention to provide the method as described above, 
further comprising the step of selecting said moiety from a group comprising a lipid, a fatty 
acid, an amino acid, a peptide, a protein, a molecule containing at least one disulfide bond, a 
liposome and any combination thereof. 
It is still within the scope of the present invention to provide the method as described above, 
further comprising the step of measuring a change in a nuclear relaxation property of said 
sample caused by a change in the antioxidant activity of said removed sample in the applied 
magnetic field. 
It is still within the scope of the present invention to provide the method as described above, 
further comprising the step of measuring a difference in Paramagnetic Relaxation 
Enhancement (PRE) property of said removed sample caused by said interaction of said FPP 
with said dissolved molecular oxygen or said “ad hoc” generated radicals. 
It is still within the scope of the present invention to provide the method as described above, 
further comprising the step of contacting said removed sample with FPP configured to form a 
liposome structure, said FPP comprising a paramagnetic core and a fatty acid moiety, 
wherein peroxidation of said fatty acid moiety substantially changes the permeability of said 
liposome. 
It is still within the scope of the present invention to provide the method as described above, 
further comprising the step of measuring a change in a nuclear relaxation property of said 
removed sample based on competition for molecular oxygen consumption. 
It is still within the scope of the present invention to provide the method as described above, 
further comprising the step of contacting said removed sample with FPP comprising a metal 
ion, oxides of a metal ion, oxides of a transition metal, mixed oxides of a transition metal and 
their mixtures or paramagnetic species. 
It is still within the scope of the present invention to provide the method as described above, 
further comprising steps of selecting said metal ion from a group comprising an ion of nickel, 
manganese, copper, gadolinium, dysprosium, europium and mixtures thereof. 
It is a further embodiment of the present invention to provide a system for establishing the 
redox potential of a production batch or continuous flow of a Foodstuff, Beverage or Wine 
(FBW), comprising: (a) a magnetic resonance device (MRD) configured to measure a change 
in a nuclear relaxation property of a sample removed from said production batch or 
continuous flow of said FBW; and, (b) a plurality of Functionalized Paramagnetic Particles 
(FPP) configured to be in contact with said removed sample, said plurality of FPP are further 
configured to change their redox potential upon interaction with dissolved molecular oxygen 
of said removed sample; wherein a change in T.sub.1 nuclear relaxation property measured 
by said MRD is correlated to the concentration of dissolved molecular oxygen of said 
removed sample of said production batch or continuous flow of said FBW, thereby 
establishing the oxidative state of said production batch or continuous flow of said FBW. 
It is a further embodiment of the present invention to provide a system for establishing the 
potability of a production batch or continuous flow of a flowable Foodstuff, Beverage or 
Wine (FBW), comprising: (a) a magnetic resonance device (MRD) configured to measure a 
change in nuclear relaxation property of a sample removed from said production batch or 
continuous flow of said FBW; and, (b) a plurality of functionalized paramagnetic particles 
(FPP) configured to be in contact with said sample, said plurality of FPP are further 
configured to change their redox potential upon interaction with dissolved molecular oxygen 
or the “ad hoc” generated radicals of said removed sample; wherein a change in T.sub.1 
nuclear relaxation property measured by said MRD correlates with dissolved molecular 
oxygen or the “ad hoc” generated radical concentration of said FBW sample, thereby 
establishing the potability of said production batch or continuous flow of said FBW. 
It is herein acknowledged that the anti-oxidant ability in wine, beverage, foodstuff or in 
biological fluids changes over time because the oxygen and oxygen contained species are 
used in oxidative reactions. Thus according to specific embodiments of the invention, the 
system of the present invention is further adapted to establish the anti-oxidant properties of a 
foodstuff, wine, beverage or biological fluid sample. 
It is further within the scope of the present invention that the term ‘hedonic scale’ refers to a 
commonly used and acceptable scale used in food science, marketing research and tasting 
panels where the respondents indicate the extent to which they either like or dislike food or 
beverage. The hedonic scale is often used for assessing the quality of wine. Hedonic scales 
commonly range from 2 (like, dislike) to 7 points. It is reported that commonly, an average 
person is able to reliably distinguish between no more than 7-9 degrees of perfection of 
quality trait. One example of such a scale is the five-point hedonic scale, which include the 
following degrees: like very much, like, is acceptable, do not like, strongly do not like. The 
hedonic scale is a universal scale, which is used in the determination of the degree of 
perfection of the assessed elements of quality, as well as clarifying the views of consumers 
about the quality of the product. 
It is also within the scope of the present invention to provide the system as defined above, 
wherein a value lower than X ml of Oxygen per liter is correlated to >7 of the 9 point hedonic 
scale. 
It is also within the scope of the present invention to provide the system as defined above, 
wherein a value lower than X ml of Oxygen per liter is correlated to >y of the hybrid scale. 
It is also within the scope of the present invention to provide the system as defined above, 
wherein a value lower than X ml of Oxygen per liter is correlated to >y of the self-adjusting 
scale. 
In a further embodiment, the system and method of the present invention is applicable for 
assessment of anti-oxidant property of a sample of interest. Such a sample may be derived of 
a biological fluid, a biological tissue, a tissue extract, an industrial fluid, food sample, a 
beverage, wine, water, a gas sample or any combination thereof. 
According to certain aspects, the anti-oxidant property may be assessed by measuring the 
redox characteristics of a sample i.e. detecting and quantifying ad hoc generated radicals. For 
this end paramagnetic particles i.e. FPP comprising a paramagnetic agent linked to a 
molecular probe may be used. 
One optional approach to evaluate the redox characteristics of a sample using the method and 
system of the present invention is by measuring the lipid peroxidation activity or properties of 
the sample. This can be achieved by using a paramagnetic probe or FPP comprising a 
paramagnetic species i.e. Gd which is functionalized with a covalently linked fatty acid 
moiety i.e. linolenic acid. The transformation of the redox characteristics of the fatty acid 
moiety may be followed by a T1 change. Such a magnetic resonance effect may reflect the 
differences in Paramagnetic relaxation enhancement (PRE) property caused by the interaction 
of the sample with the macromolecular paramagnetic system. 
According to an alternative approach, the paramagnetic probe i.e. comprising a Gd entity 
linked to a fatty acid moiety is a part of a liposome structure. In such a case, the peroxidation 
of the fatty acid moiety may change the permeability of the liposome membrane and thus 
affect the measured nuclear relaxation property of the sample. 
According to yet another embodiment, the assessment of anti-oxidant property of a sample of 
interest may be performed using methods based on competition for oxygen consumption or 
redox characteristics. In such an example the FPP complex as disclosed herein above may 
contain a metal ion such as Mn(II) as a paramagnetic species, that upon interaction with 
hyperoxide or superoxide radicals transforms its oxidation state i.e. to Mn (III). The change 
in the oxidation state of the paramagnetic species may generate T1 effect in 1H-relaxometric 
assay measured by NMR or MRI technique. According to yet another embodiment, the anti-
oxidant property of a sample of interest may be assessed using a paramagnetic (i.e. Gd) 
complex where the measured T1 is dependent on the formation and cleavage of disulfide (s-s) 
bonds within the functionalized macromolecular probe linked to the paramagnetic moiety. 
Reference is now made to FIG. 1 showing a schematic representation of a system and 
procedure, for detection of a predetermined epitope or receptor, on a cell membrane, using 
the targeted functionalized paramagnetic particles or probes (FPP) of the present invention. 
Such a system and method can be useful, for example, for assessment of folate receptors 
within a biological sample. In this figure, the paramagnetic probe is a liposome 100 loaded 
with a plurality of paramagnetic species or cores 30. In this embodiment, the liposome 100 is 
conjugated with a target moiety 10 through a spacer 20, which may comprise for example a 
pegylated chain. The target moiety 10 can be a ligand (i.e. folic acid or a folic acid derivative) 
that is adapted to interact or bind with its corresponding receptor 50 (i.e. folate receptor) that 
may be located on the cellular surface or membrane 70 of a cell 200. The target moiety 10 is 
allowed to bind with the receptor 50 and the non bound liposomes are then removed. The 
sample, which includes the bound liposomes loaded with paramagnetic species, is exposed to 
an applied magnetic field configured to measure a change in nuclear relaxation property of 
the sample. The change in the measured T.sub.1 nuclear relaxation property in the applied 
magnetic field indicates the presence of the specific receptor in the analysed sample. 
Furthermore, the difference in the measured Paramagnetic Relaxation Enhancement (PRE) 
properties is correlated with the concentration of the receptor within the tested sample. 
According to a further embodiment, the paramagnetic core 30, embedded within the liposome 
membrane, comprise Mn(II) ions. In a specific example, each liposome is loaded with about 
4*105 Mn(II) ions. In a further embodiment, the target moiety 10, which is conjugated to the 
liposome membrane, is folate. In such an example, about 9*105 folate residues are exposed 
per liposome. In a cell binding experiment using Human Ovarian Cancer cells (IGROV-1) 
overexpressing folate receptors 50 at the cell membrane 70, about 5000 liposomes were 
found to be bound to each cell. In such an embodiment, the total cell surface is covered by 
liposomes, thus it is difficult to discriminate between cells with different receptor expression 
level. 
Reference is now made to FIG. 2 showing schematic representation of a multi step procedure, 
using the functionalized paramagnetic particles or probes of the present invention, for 
detection of a predetermined epitope or receptor, on a cell membrane. In such an 
embodiment, biotinylated liposomes 100 are prepared, containing about 105 paramagnetic 
centers 30 per liposome and biotin residues 60 conjugated with the liposome membrane by a 
spacer 20. The biotinylated liposomes are added to a sample containing cells 200 expressing 
folate receptors 50 at their membrane surface 70, activated streptavidin molecules 80, and 
folic acid residues 10 linked to biotin residues 60. The site specific residues (i.e. biotin-
streptavidin and folic acid residues-folate receptors) are allowed to specifically bind to each 
other and a subsequent washing step of unbound residues is followed. The sample containing 
the bound paramagnetic liposomes is then exposed to a magnetic field and a change in a 
nuclear relaxation property (i.e. T1 and/or T2) of the sample is measured. The 
aforementioned change in a nuclear relaxation property (i.e. T1 and/or T2) of the sample is 
correlated with the presence and/or concentration of the target molecule, for example the 
expressed folate receptors on a cellular membranes. 
It is thus one embodiment of the present invention to provide an efficient self-fastening cage 
of a MRD (300) for providing a homogeneous, stable and uniform magnetic field therein, 
characterized by an outside shell comprising at least three flexi-jointed superimposed metal 
alloy walls (1). 
It is also in the scope of the present invention to provide the aforementioned MRD further 
comprising at least six side-magnets (2) arranged in two equal groups configured in a face-to-
face orientation, in a magnetic connection with the cage walls (1), increasing the overall 
strength of the magnetic field provided in said cage; at least two pole-pieces (3), arranged in a 
face-to-face orientation in between side-magnets (2); and, at least two main-magnets (4), 
located on said pole-pieces (3), arranged in a face-to-face orientation, generating the static 
magnetic field therein said cage. 
Reference is made now to FIG. 7, schematically presenting a partial sectional top and out of 
scale view, with respect to an axial plane of the 3D MRD (300) wherein the shape of a square 
parallelepiped is provided, having four cage walls (1), four side magnets (2); and a pole-piece 
(3); said cage walls and side-magnets are essentially interconnected in a superimposed 
manner such that a self-fastening cage is obtained. 
Reference is made now to FIG. 8, schematically presenting an entire perspective view of the 
of the 3D MRD, having two cage walls (1), eight side magnets (2); two pole-pieces (3); two 
main magnet (4) and eight square corner-magnets (5) and four cylinder corner-magnets 
located inside the pole-pieces; all of them are arranged in two equal groups face-to-face 
orientation. 
In another embodiment, a high contrast, high resolution magnetic resonance device i.e. MRI 
is provided. A non-limiting example of an embodiment of this type is schematically 
illustrated in FIG. 4. The device (400) comprises two sets of magnets (420, 430). The RF 
coils (not shown) are part of an envelope (440) which contains the sample to be analyzed 
(410). In this embodiment, the high magnetic field magnets (420) are in a horizontal 
orientation, while the low magnetic field magnets (430) are in a vertical orientation. In other 
embodiments, the low field magnets can be inside the high magnetic field magnets. In yet 
other embodiments, the low magnetic field magnets can be outside the high magnetic field 
magnets. Such embodiments can be used in the methods and systems as disclosed herein. 
EXAMPLES 
Various examples were carried out to prove the embodiments claimed in the present 
invention. Some of these experiments are referred hereinafter. The examples describe the 
manner and process of the present invention and set forth the best mode contemplated by the 
inventors for carrying out the invention, but are not to be construed as limiting the invention. 
Example 1 
Assessment of Anti-Oxidant Activity (AOA) in Liquid or Beverage Samples, Such as 
Wine or Spirits or Liquors 
It is herein acknowledged that AOA prevents lipid peroxidation. In this embodiment, the 
paramagnetic-probe complex that is used, contains a Gd paramagnetic core that is 
functionalized with a linoleinic acid moiety (L). Upon interaction of the GD complex (GD-
L), with oxygen-based radicals, lipid peroxide products are produced, as schematically shown 
in the following reaction: 
 
Gd-L→Gd-LO2.→products  
The aforementioned lipid transformation process can be followed by T1-change, which may 
exploit and reflect differences in Paramagnetic Relaxation Enhancement (PRE) upon 
interaction with the macromolecular paramagnetic complex system. 
In an alternative embodiment, Gd-L is part of a liposome structure; the peroxidation of L 
changes the permeability of the liposome membrane and thus affects the measured T.sub.1 
nuclear relaxation property of the sample. 
In an alternative embodiment, competition assays for oxygen consumption and/or redox 
characteristics are used, based on the system and method as herein described. Such systems 
may comprise a Mn(II)-containing paramagnetic probe that transforms into a Mn(III) 
complex. This transformation may result a T1 nuclear relaxation property effect. In a further 
example, such a system may comprise a Gd macromolecular complex or probe, where T1 is 
dependent on the formation and/or cleavage of disulfide (S—S) bonds within the 
macromolecular probe. 
Example 2 
Assessment of Epitopes on Cell Membranes 
Reference is now made to FIG. 3 schematically describing a further embodiment of the 
method for assessment of cell receptors using the functionalized paramagnetic particles (FPP) 
of the present invention. In this embodiment, paramagnetic functionalized liposomes, for 
example paramagnetic particles as described in FIG. 1 or FIG. 2, are incubated with a sample 
containing cells suspected to express a receptor of interest. Following a washing step of 
unbound liposomes, disruption of the bound liposome sample, for example by a sonication 
procedure, is performed. In a further specific embodiment, Human Serum Albumin (HSA) 
(about 40 mg/ml) is added to the disrupted cell sample containing the suspended 
paramagnetic cores. A relaxometric measurement is then performed for determining PRE 
properties of the sample. The change in PRE as compared with a control sample indicates the 
presence and/or concentration of the tested target epitope, for example a cell receptor. 
Reference is now made to FIG. 4 showing a graphic representation of the relaxometric 
measurement results over extended range of frequencies (MHz). As can be seen, after 
sonication and addition of HSA (40 mg/ml) to the sample containing cells expressing a 
specific epitope and functionalized paramagnetic liposomes adapted to interact with the 
epitope, as described above, a specific peak in the relaxativity value was shown in the rage of 
frequencies of about 20-40 MHz. 
In order to evaluate the affect of the concentration of the paramagnetic agent used in the FPP, 
samples containing different Mn(II) ion concentration, undergone liposome sonication and 
HSA (40 mg/ml) addition, were exposed to electromagnetic frequencies of 20 MHz and were 
subjected to a relaxometric measurement. Reference is now made to FIG. 5, showing a 
graphic representation of relaxation rate measurement results at different Mn(II) ion 
concentration. As can be seen in this figure, a direct correlation was observed between 
concentrations of the paramagnetic core (i.e. Mn(II) ions) used within the FPP, and the 
measured relation rate. It can be further concluded that a value of about 5 μM Mn 
concentration was the lowest detectable Mn(II) ion concentration. 
The above described experiment shows that Mn(II) ion concentration of [Mn]=5 mM 
corresponds to 1.5×109 liposome particles in 200 μl. In one embodiment, the number of 
liposome particles (FPP) is calculated according to the following equation: 
No. of receptors per cell×No of cells ≧1.5×109  
Thus, in the case of 1×106 receptors per cell, 1500 cells are necessary to enable detection of a 
desirable expressed receptor using the minimal required concentration of Mn(II) ions 
containing paramagnetic liposomes. 
Example 3 
Paramagnetic Liposome Preparation 
According to certain embodiments of the present invention, functionalized paramagnetic 
liposome particles are prepared. The 1st step of the process may include the preparation of 
thin lipidic film. In one embodiment, the film comprises the following ingredients (20 
mg/ml): 
DPPC 77% Cholesterol 20% DSPE-methoxy-PEG2000  2% DSPE-target moiety (i.e.folate)-
PEG2000  1%  
 Reference is now made to FIG. 6 schematically describing optional steps in the 
functionalized paramagnetic liposome (FPP) preparation process. In one embodiment, the 2nd 
step of the process includes the mixing of the lipidic film with an isotonic solution containing 
the Mn(II) ions and the hydration of the mixture. In the 3rd step, multilamellar vesicles (MLV) 
are prepared by vortexing the hydrated mixture at 55° C. This step is followed by a 4th step of 
extrusion at 55° C. to obtain large unilamellar vesicles (LUV) with a mean diameter of above 
50 nm, preferably between about 120 nm and 140 nm. In the 5th step the LUV preparation is 
then subjected to a TET A treatment and dialysis to obtain the functionalized paramagnetic 
liposomes. 
FIGS. 1 to 9 and examples thus establish the applicability and enable, inter alia, each and all 
which follows: 
A novel method for detecting a target biochemical molecular species or at least one property 
correlated with the occurrence of said biochemical molecular species in a sample whose main 
component is water, comprising steps of (a) obtaining a sample whose main component is 
water; (b) providing Functionalized Paramagnetic Particles (FPP) comprising a paramagnetic 
core and a moiety configured to interact with said target biochemical molecular species or 
with molecules collectively reporting on a property of said target biochemical molecular 
species; (c) contacting said FPP with said sample; (d) exposing said sample to an applied 
magnetic field; (e) measuring a change in a nuclear relaxation property of said sample, 
caused by said interaction between said FPP and said biochemical molecular species or said 
molecules collectively reporting on a property of said target biochemical molecular species; 
in the applied magnetic field; and, correlating said change to the presence of said biochemical 
molecular species in said sample or to at least one property correlated with the occurrence of 
said biochemical molecular species in said sample; wherein a change in T.sub.1 nuclear 
relaxation property of the water protons in said sample is correlated to the presence of said 
target biochemical molecular species or to at least one property correlated with the 
occurrence of said biochemical molecular species in said sample, further wherein said FPP 
comprises a non ferrous oxide paramagnetic core. 
A method as defined in any of the above, comprising at least one additional step; said step is 
selected from a group consisting of one or more of the following:  
 a. performing two or more measurements to determine the relaxation time of the 
sample, wherein the measurements are performed before and after at least one 
addition of said FPP; 
 b. detecting said target biochemical molecular species and/or characterizing at least 
one property correlated with the occurrence of said biochemical molecular species in 
vitro; 
 c. forming said FPP as a single molecule, a multimeric system, a micro-sized vesicle 
or particle, a nano-sized vesicle or particle, a liposome, a probe or any combination 
thereof; 
 d. selecting said sample from a group consisting of a liquid, a gas, a slurry, a liquid 
containing particulates, a gas containing particulates, a gel, a sol, a suspension, a 
solution, a dispersion, a colloid, a mixture, an emulsion, an aerosol, a liquid 
containing solid objects, a gas containing solid objects, and any combination thereof; 
 e. selecting said sample from a group comprising a biological fluid, a biological 
tissue, a tissue extract, an industrial fluid, food sample, a beverage, wine, water, 
potable water, sewage, irrigation water, sea water, river water, lake water, industrial 
effluent, farm effluent, effluent from human habitation, road runoff, cleaning fluid, a 
gas sample or any combination thereof; 
 f. selecting said biological fluid from a group comprising urine, blood, lymph, plasma, 
cerebrospinal fluid, saliva, amniotic fluid, bile and tears; 
 g. providing said sample within a production process; 
 h. selecting said production process in an industrial area, said industrial area is a 
member of a group consisting of the pharmaceuticals, food production, beverage 
production, chemical refining, chemical processing, medical products, biological 
products, metal casting, metal refining, desalination, fluid purification, and sewage 
processing; 
 i. analyzing at least one characteristic or property of said target molecular species, 
said characteristic or property is selected from a group comprising concentration, 
permeability, oxidation state, redox characteristic (reduction-oxidation state), 
activation state and any combination thereof; 
 j. applying a magnetic field, thereby enhancing the change in a paramagnetic nuclear 
relaxation property of said sample upon comparing relaxation rates at two different 
magnetic fields; 
 k. measuring a change in a nuclear relaxation property of said sample using a portable 
NMR or MRI measuring means; 
 l. measuring a change in a nuclear relaxation property of said sample using a magnetic 
resonance device (MRD) consisting of magnets housed within a cage; and 
 m. measuring a change in a nuclear relaxation property of said sample using a self-
fastening cage type of a magnetic resonance device (MRD). 
In a self-fastening cage of a magnetic resonance device (MRD) (300), a method according to 
claim 1 comprising at least one additional step; said step is selected from a group consisting 
of one or more of the following:  
 a. providing a homogeneous, stable and uniform magnetic field therein, further 
wherein said self-fastening cage type MRD additionally characterized by an outside 
shell comprising at least three flexi-jointed superimposed walls (1); 
 b. providing an MRD characterized by an outside shell; said outside shell comprising 
at least three flexi-jointed superimposed walls (1) disposed in a predetermined 
clockwise or counterclockwise arrangement; said MRD comprising: at least six side-
magnets (2) arranged in two equal groups being in a face-to-face orientation in a 
magnetic connection with said outside shell, increasing the overall strength of the 
magnetic field provided in said cage; at least two pole-magnet pieces (3), arranged in 
a face-to-face orientation in between said side-magnets (2); at least two main-magnets 
(4), located on said pole-pieces (3), arranged in a face-to-face orientation, generating 
the static magnetic field therein said cage; and, shimming mechanism, said 
mechanism is selected from a group consisting of an array of active shim coils, 
passive shimming elements or a combination thereof; wherein at least a portion of 
said side-magnets (2) are superconductors or ferromagnets; 
 c. providing a magnetic resonance device adapted to producing high contrast high 
resolution images of said sample; 
 d. providing a magnetic resonance device comprising: an envelope for least partially 
confining said sample; a plurality of magnets located at least partially around said 
envelope, said plurality of magnets comprising: a least one first magnet configured to 
provide a high magnetic field for generating multiple time-resolved one or more first 
images at high resolution of at least a portion of said sample; and a least one second 
magnet configured to provide a low magnetic field for generating multiple time-
resolved one or more second images at high contrast of at least portion of same said 
sample; wherein at least one image of said first images and at least one image of said 
second images being generated in a time no greater than approximately the time 
between two first images; and, a CPU to process said images comprising a computer 
readable medium containing instructions for generating at least one third image 
superimposing at least one image of said first images with at least one image of said 
second images; 
 e. generating multiple time resolved one or more first images at high resolution of at 
least a portion of said sample; generating multiple time resolved one or more second 
images at high contrast of at least portion of same said sample; and then 
superimposing at least one image of said first images with at least one image of said 
second images; whereby a high-contrast, high resolution real-time continuous image 
of said sample is obtained; 
 f. selecting said at least one first magnet to be of 2 Tesla and lower; 
 a. selecting said at least one first magnet to be of 2 Tesla and higher; 
 b. said at least one first magnet from a group consisting of permanent magnets, 
electromagnets, superconducting magnets, and any combination thereof; 
 c. selecting said at least one second magnet to be of 2 Tesla and lower; 
 d. selecting said at least one second magnet to be of 2 Tesla and higher; 
 e. selecting said at least one second magnet from a group consisting of permanent 
magnets, electromagnets, superconducting magnets, and any combination thereof; 
 f. generating a magnetic resonance signal in the range of about 0.1 Tesla and about 10 
Tesla; 
 g. generating a magnetic resonance signal in the range of 2 Tesla and lower; 
 h. generating a magnetic resonance signal in the range of 2 Tesla and higher; 
 i. applying a magnetic resonance frequency in the range of about 5 MHz to about 40 
MHz; 
 j. selecting said magnets from a group consisting of permanent magnets, 
electromagnets, superconducting magnets, and any combination thereof; 
 k. selecting said moiety from a group comprising antibodies, antibody fragments, 
monoclonal antibody, receptors, ligands, macromolecules, peptides, hormones, fatty 
acids, lipids, receptor agonists and antagonists, amino acids, sugars, lectins, albumins, 
polycarbon molecules, glycoproteins, nucleic acids, pegylated molecules, liposomes, 
chelators, cells, viruses, chemotherapeutic agents and any combination thereof; 
 l. selecting said target biochemical molecular species from a group comprising a 
biological molecule, a chemical molecule, an analyte, a contaminant, a particle, a 
pathogen or any combination thereof; 
 m. selecting said target biochemical molecular species from a group comprising a 
protein, a pathogen, a prion, a virus, a bacteria, a contaminant, a pathological isoform, 
a biomarker, an allergen, a neurotransmitter, an antigenic determinant, an epitope, a 
cell marker, cell membrane marker or epitope, a membrane marker, an enzyme, a 
chemical molecule, an analyte, a receptor, a ligand, a macromolecule, a peptide, a 
hormone, a fatty acid, a lipid, a receptor agonist and antagonist, an amino acid, a 
sugar, a glycoprotein, a nucleic acid, an antioxidant agent, a chemotherapeutic agent, 
a biological tissue and any combination thereof; 
 n. selecting said analyte from a group comprising an organic analyte and an inorganic 
analyte; 
 o. selecting said inorganic analyte from a group comprising molecular oxygen, 
oxygen-containing radicals and combinations thereof; detecting oxygen-containing 
radicals “ad hoc” generated, for assessing the anti-oxidant properties of the sample; 
 p. selecting said paramagnetic core as a metal ion, a metal complex, oxides of a metal 
ion, oxides of a transition metal, mixed oxides of a transition metal and their mixtures; 
 q. selecting said paramagnetic core from a group comprising metal complexes, 
aggregates of metal complexes, polymer-bound metal complexes, stable organic 
radicals and any combination thereof; 
 r. selecting said metal ion from a group comprising an ion of nickel, iron, manganese, 
copper, gadolinium, europium and mixtures thereof; 
 s. assessing redox characteristics, comprising steps of detecting differences in 
Paramagnetic Relaxation Enhancement (PRE) properties induced by a change in at 
least one redox characteristic of said FPP, using an applied magnetic field; 
 t. selecting said redox characteristic from a group comprising lipid peroxidation, lipid 
peroxidation followed by a change in membrane permeability, redox potential of 
metal ions, formation and cleavage of disulfide bonds, oxidation state, antioxidant 
activity and any combination thereof; 
 u. providing said FPP as a liposome loaded with a plurality of paramagnetic payloads; 
 v. applying a magnetic field, thereby enhancing a change in the permeability of said 
liposome so as to affect a nuclear relaxation property of said sample; 
 w. applying a magnetic field, thereby enhancing a change in at least one of cleavage 
or formation of disulfide bonds of said moiety so as to affect a nuclear relaxation 
property of said sample; 
 x. applying a magnetic field, thereby affecting at least one property of said FPP 
selected from a group comprising concentration, lipid peroxidation, membrane 
permeability, redox potential, formation and cleavage of disulfide bonds, oxidation 
state, redox potential, activation state, binding affinity, and any combination thereof, 
so as to induce a change in a nuclear relaxation property of said sample; 
 y. conjugating said liposome with a site-specific ligand; 
 z. conjugating said liposome with a biotin activated molecule; and 
 aa. providing said FPP as a biotinylated liposome. 
A method for detection of a biomarker in a sample whose main component is water, 
comprising steps as follows:  
 a. obtaining a sample whose main component is water; 
 b. providing liposomes loaded with a plurality of paramagnetic agents, said liposomes 
are conjugated with a site specific moiety configured to interact with said biomarker 
in said sample; 
 c. contacting said liposomes with said sample under conditions that allow the 
interaction between the site specific moiety and said biomarker; 
 d. exposing said sample to an applied magnetic field; and, 
 e. measuring a change in a nuclear relaxation property of said sample caused by said 
interaction between the liposomes and said biomarker in the applied magnetic field;  
wherein a change in T.sub.1 nuclear relaxation property is correlated to the presence 
of said biomarker in said sample.  
A method as defined above, wherein the method further comprising one or more steps as 
follows:  
 a. providing biotinylated liposomes; said liposomes loaded with a plurality of 
paramagnetic agents; 
 b. providing biotinylayed ligands, said ligands configured to interact with said 
biomarker; 
 c. providing activated avidin molecules; 
 d. contacting said biotinylated liposomes, said biotinylayed ligands and said activated 
avidin molecules with said sample so as to enable avidin-biotin interaction, thereby 
forming complexes comprising said liposomes, said ligand and said biomarker; such 
that said complexes are specific to said biomarker; and, 
 e. measuring a change in a nuclear relaxation property of said sample caused by said 
complex formation in the applied magnetic field;  
wherein a change in T.sub.1 nuclear relaxation property is correlated to the presence 
of said biomarker in said sample.  
A system for detecting a target biochemical molecular species or at least one property 
correlated with the occurrence of said biochemical molecular species in a sample whose main 
component is water, comprising a magnetic resonance device (MRD) configured to measure 
a change in nuclear relaxation property of said sample; and, a plurality of Functionalized 
Paramagnetic Particles (FPP) said FPP comprising a paramagnetic core and a moiety 
configured to interact with said target biochemical molecular species or with molecules 
collectively reporting on a property of said target biochemical molecular species; wherein a 
change in T.sub.1 nuclear relaxation property of water protons in said sample measured by 
said MRD is correlated to the presence of said target biochemical molecular species and/or to 
the at least one property correlated with the occurrence of said biochemical molecular species 
in said sample, further wherein said FPP comprises a non-ferrous oxide paramagnetic core. 
The system as defined above wherein the system further comprising means for detecting said 
target biochemical molecular species and/or characterizing at least one property correlated 
with the occurrence of said biochemical molecular species in vitro. 
The system as defined in any of the above, wherein the FPP is formed as a single molecule, a 
multimeric system, a micro-sized vesicle or particle, a nano-sized vesicle or particle, a 
liposome, a probe and any combination thereof. 
The system as defined in any of the above, wherein the sample is selected from a group 
consisting of a liquid, a gas, a slurry, a liquid containing particulates, a gas containing 
particulates, a gel, a sol, a suspension, a solution, a dispersion, a colloid, a mixture, an 
emulsion, an aerosol, a liquid containing solid objects, a gas containing solid objects, and any 
combination thereof. 
The system as defined in any of the above, wherein the sample is further selected from a 
group comprising a biological fluid, a biological tissue, a tissue extract, an industrial fluid, 
food sample, a beverage, wine, water, potable water, sewage, irrigation water, sea water, river 
water, lake water, industrial effluent, farm effluent, effluent from human habitation, road 
runoff, cleaning fluid, a gas sample or any combination thereof. 
The system as defined in any of the above, wherein the biological fluid is selected from a 
group comprising urine, blood, lymph, plasma, cerebrospinal fluid, saliva, amniotic fluid, bile 
and tears. 
The system as defined in any of the above, wherein the sample is provided within a 
production process. 
The system as defined in any of the above, wherein the production process is in an industrial 
area, said industrial area is a member of a group consisting of the pharmaceuticals, food 
production, beverage production, chemical refining, chemical processing, medical products, 
biological products, metal casting, metal refining, desalination, fluid purification, and sewage 
processing. 
The system as defined in any of the above, wherein the property is selected from a group 
comprising concentration, permeability, oxidation state, redox characteristic (reduction-
oxidation state), activation state and any combination thereof. 
The system as defined in any of the above, wherein the magnetic resonance device (MRD) is 
configured to enhance the change in a paramagnetic nuclear relaxation property of said 
sample upon comparing relaxation rates at two different magnetic fields. 
The system as defined in any of the above, wherein the magnetic resonance device (MRD) is 
a portable NMR or MRI measuring means. 
The magnetic resonance device (MRD) consists of magnets housed within a cage. 
The system as defined in any of the above, wherein the magnetic resonance device (MRD) is 
a self-fastening cage type of a magnetic resonance device (300). 
In a self-fastening cage of a magnetic resonance device (MRD) (300), a system as defined 
above, wherein said self-fastening cage type MRD additionally characterized by an outside 
shell comprising at least three flexi-jointed superimposed walls (1). 
In a self-fastening cage type MRD (300), a system as defined above, said system further 
comprises an MRD characterized by an outside shell; said outside shell comprising at least 
three flexi-jointed superimposed walls (1) disposed in a predetermined clockwise or 
counterclockwise arrangement; said MRD comprising: at least six side-magnets (2) arranged 
in two equal groups being in a face-to-face orientation in a magnetic connection with said 
outside shell, increasing the overall strength of the magnetic field provided in said cage; at 
least two pole-magnet pieces (3), arranged in a face-to-face orientation in between said side-
magnets (2); at least two main-magnets (4), located on said pole-pieces (3), arranged in a 
face-to-face orientation, generating the static magnetic field therein said cage; and, a 
shimming mechanism, said mechanism is selected from a group consisting of an array of 
active shim coils, passive shimming elements or a combination thereof; wherein at least a 
portion of said side-magnets (2) are superconductors or ferromagnets. 
The system as defined in any of the above, wherein the MRD is configured to produce high 
contrast high resolution images of said sample. 
The system as defined in any of the above, wherein the magnetic resonance device 
comprising an envelope for least partially confining said sample; a plurality of magnets 
located at least partially around said envelope, said plurality of magnets comprising: a least 
one first magnet configured to provide a high magnetic field for generating multiple time-
resolved one or more first images at high resolution of at least a portion of said sample; and a 
least one second magnet configured to provide a low magnetic field for generating multiple 
time-resolved one or more second images at high contrast of at least portion of same said 
sample; wherein at least one image of said first images and at least one image of said second 
images being generated in a time no greater than approximately the time between two first 
images; and, a CPU to process said images comprising a computer readable medium 
containing instructions for generating at least one third image superimposing at least one 
image of said first images with at least one image of said second images, whereby a high 
contrast, high resolution real time continues image of said sample is obtained. 
The system as defined in any of the above wherein at least one of the following is held true: 
said at least one first magnet is of 2 Tesla and lower; said at least one first magnet is of 2 
Tesla and higher; said at least one first magnet is selected from a group consisting of 
permanent magnets, electromagnets, superconducting magnets, and any combination thereof; 
said at least one second magnet is of 2 Tesla and lower; said at least one second magnet is of 
2 Tesla and higher; at least one second magnet is selected from a group consisting of 
permanent magnets, electromagnets, superconducting magnets, and any combination thereof; 
said magnetic resonance device (MRD) is configured to generate a magnetic resonance signal 
in the range of about 0.1 Tesla and about 10 Tesla; said magnetic resonance device (MRD) is 
configured to generate a magnetic resonance signal in the range of 2 Tesla and lower; said 
magnetic resonance device (MRD) is configured to generate a magnetic resonance signal in 
the range of 2 Tesla and higher; said magnetic resonance device (MRD) is configured to 
generate a magnetic resonance frequency in the range of about 5 MHz to about 40 MHz; said 
magnets are selected from a group consisting of permanent magnets, electromagnets, 
superconducting magnets, and any combination thereof; said moiety is selected from a group 
comprising antibodies, antibody fragments, monoclonal antibody, receptors, ligands, 
macromolecules, peptides, hormones, fatty acids, lipids, receptor agonists and antagonists, 
amino acids, sugars, lectins, albumins, polycarbon molecules, glycoproteins, nucleic acids, 
pegylated molecules, liposomes, chelators, cells, viruses, chemotherapeutic agents and any 
combination thereof; said target biochemical molecular species is selected from a group 
comprising a biological molecule, a chemical molecule, an analyte, a contaminant, a particle, 
a pathogen or any combination thereof; said target biochemical molecular species is selected 
from a group comprising a protein, a pathogen, a prion, a virus, a bacteria, a contaminant, a 
pathological isoform, a biomarker, an allergen, a neurotransmitter, an antigenic determinant, 
an epitope, a cell marker, cell membrane marker or epitope, a membrane marker, an enzyme, 
a chemical molecule, an analyte, a receptor, a ligand, a macromolecule, a peptide, a hormone, 
a fatty acid, a lipid, a receptor agonist and antagonist, an amino acid, a sugar, a glycoprotein, 
a nucleic acid, an antioxidant agent, a chemotherapeutic agent, a biological tissue and any 
combination thereof said analyte is selected from a group comprising an organic analyte and 
an inorganic analyte; said inorganic analyte is selected from a group comprising molecular 
oxygen, oxygen-containing radicals and combinations thereof; said oxygen-containing 
radicals are “ad hoc” generated radicals, for assessing the anti-oxidant properties of the 
sample; said paramagnetic core is selected from a group comprising a metal ion, a metal 
complex, oxides of a metal ion, oxides of a transition metal, mixed oxides of a transition 
metal and their mixtures; said metal ion is selected from a group comprising an ion of nickel, 
iron, manganese, copper, gadolinium, europium and mixtures thereof; said redox 
characteristic is selected from a group comprising lipid peroxidation, lipid peroxidation 
followed by a change in membrane permeability, redox potential of metal ions, formation and 
cleavage of disulfide bonds, oxidation state, antioxidant activity and any combination thereof; 
said FPP is a liposome loaded with a plurality of paramagnetic payloads; said system further 
comprising means for enhancing a change in the permeability of said liposome so as to affect 
a nuclear relaxation property of said sample; said system is adapted to detect a change in at 
least one of cleavage or formation of disulfide bonds of said moiety so as to affect a nuclear 
relaxation property of said sample; said property correlated with the occurrence of said 
biochemical molecular species is selected from a group comprising concentration, lipid 
peroxidation, membrane permeability, redox potential, formation and cleavage of disulfide 
bonds, oxidation state, redox potential, activation state, binding affinity, and any combination 
thereof; said liposome is conjugated with a site-specific ligand; said liposome is conjugated 
with a biotin activated molecule; and said FPP is a biotinylated liposome. 
A system for detection of a biomarker in a sample whose main component is water, 
comprising: a sample whose main component is water; liposomes loaded with a plurality of 
paramagnetic agents, said liposomes are conjugated with a site specific moiety configured to 
interact with said biomarker in said sample; a magnetic resonance device (MRD) configured 
to measure a change in a nuclear relaxation property of a sample whose main component is 
water removed from said production batch or continuous flow of said FBW or biological 
fluid; wherein a change in T.sub.1 nuclear relaxation property of the water protons in said 
sample is correlated to the presence of said biomarker in said sample. 
Use of Functionalized Paramagnetic Particles (FPP) to detect the presence or at least one 
other characteristic of a target biochemical molecular species within a sample whose main 
component is water, said FPP comprising a paramagnetic core and a moiety configured to 
interact with said target biochemical molecular species or with molecules collectively 
reporting on a property of said target biochemical molecular species; wherein a change in 
T.sub.1 nuclear relaxation property of water protons within said sample measured by a 
generated applied magnetic field is correlated to the presence or at least one other 
characteristic of said target biochemical molecular species in said sample. 
The use as defined above further adapted to detect at least one property correlated with the 
occurrence of said biochemical molecular species in said sample. 
A method of establishing the redox properties of a production batch or continuous flow of a 
Foodstuff, Beverage or Wine (FBW) or of a biological fluid, comprising the steps of 
obtaining a sample removed from said production batch or continuous flow of said FBW or 
from said biological fluid; providing Functionalized Paramagnetic Particles (FPP) configured 
to change their redox property upon interaction with dissolved molecular oxygen or “ad hoc” 
generated radicals of said removed sample; contacting said FPP with said removed sample; 
exposing said removed sample to an applied magnetic field; and, measuring a change in a 
nuclear relaxation property of said removed sample caused by said change in the redox 
properties of said FPP in the applied magnetic field; wherein a change in T.sub.1 nuclear 
relaxation property is correlated with the presence and/or concentration of said molecular 
oxygen or of the “ad hoc” generated radicals of said removed sample, thereby establishing 
the redox properties of said production batch or continuous flow of said FBW or of said 
biological fluid. 
The method as defined above, wherein the method further comprising at least one step, said 
step or steps is/are selected from a group consisting of the following: providing said FPP 
conjugated with at least one moiety configured to interact with dissolved molecular oxygen 
or with “ad hoc” generated radicals; selecting said moiety from a group comprising a lipid, a 
fatty acid, an amino acid, a peptide, a protein, a molecule containing at least one disulfide 
bond, a liposome and any combination thereof; measuring a change in a nuclear relaxation 
property of said sample caused by a change in the antioxidant activity of said removed 
sample in the applied magnetic field; measuring a difference in Paramagnetic Relaxation 
Enhancement (PRE) property of said removed sample caused by said interaction of said FPP 
with said dissolved molecular oxygen or with said “ad hoc” generated radicals; contacting 
said removed sample with FPP configured to form a liposome structure, said FPP comprising 
a paramagnetic core and a fatty acid moiety, wherein peroxidation of said fatty acid moiety 
substantially changes the permeability of said liposome; measuring a change in a nuclear 
relaxation property of said removed sample based on competition for molecular oxygen 
consumption; providing said FPP comprising a paramagnetic core selected from a group 
comprising a metal ion, a metal complex, oxides of a metal ion, oxides of a transition metal, 
mixed oxides of a transition metal and their mixtures; selecting said metal ion from a group 
comprising an ion of nickel, iron, manganese, copper, gadolinium, dysprosium, europium and 
mixtures thereof; and selecting said biological fluid from a group comprising urine, blood, 
lymph, plasma, cerebrospinal fluid, saliva, amniotic fluid, bile and tears. 
A system for establishing the redox properties of a production batch or continuous flow of a 
Foodstuff, Beverage, Wine (FBW) or of a biological fluid, comprising: a magnetic resonance 
device (MRD) configured to measure a change in a nuclear relaxation property of a sample 
removed from said production batch or continuous flow of said FBW or of said biological 
fluid; and, a plurality of Functionalized Paramagnetic Particles (FPP) configured to be in 
contact with said removed sample, said plurality of FPP are further configured to change at 
least one of their redox properties upon interaction with dissolved molecular oxygen or with 
“ad hoc” generated radicals of said removed sample; wherein a change in T.sub.1 nuclear 
relaxation property measured by said MRD is correlated to the presence or concentration of 
dissolved molecular oxygen or “ad hoc” generated radicals of said removed sample, thereby 
the redox properties of said production batch or continuous flow of said FBW or of said 
biological fluid are established. 
The system according as defined above, wherein said biological fluid is selected from a group 
comprising urine, blood, lymph, plasma, cerebrospinal fluid, saliva, amniotic fluid, bile and 
tears. 
A system for establishing the potability of a production batch or continuous flow of a 
flowable Foodstuff, Beverage or Wine (FBW), comprising: a magnetic resonance device 
(MRD) configured to measure a change in nuclear relaxation property of a sample removed 
from said production batch or continuous flow of said flowable FBW; and, a plurality of 
functionalized paramagnetic particles (FPP) configured to be in contact with said sample, 
said plurality of FPP are further configured to change their redox/oxidative properties upon 
interaction with dissolved molecular oxygen or “ad hoc” generated radicals of said removed 
sample; wherein a change in T.sub.1 nuclear relaxation property measured by said MRD 
correlates with dissolved molecular oxygen or “ad hoc” generated radicals concentration of 
said FBW sample, thereby establishing the potability of said production batch or continuous 
flow of said flowable FBW. 
The system according as defined above, wherein at least one of the following is held true: a 
concentration value lower than about 6 ml of dissolved oxygen per liter of said removed 
sample is indicative of the potability of said production batch or continuous flow of said 
FBW; a value lower than X ml of oxygen per liter is correlated to >7 of the 9 point hedonic 
scale; a value lower than X ml of oxygen per liter is correlated to >y of the hybrid scale; and 
a value lower than X ml of oxygen per liter is correlated to >y of the self-adjusting scale. 
Claims 
1. A method for detecting a target biochemical molecular species or at least one property 
correlated with the occurrence of said biochemical molecular species in a sample whose main 
component is water, comprising steps of; wherein a change in T.sub.1 nuclear relaxation 
property of the water protons in said sample is correlated to the presence of said target 
biochemical molecular species or to at least one property correlated with the occurrence of 
said biochemical molecular species in said sample, further wherein said FPP comprises a non 
ferrous oxide paramagnetic core. 
a. obtaining a sample whose main component is water; 
b. providing Functionalized Paramagnetic Particles (FPP) comprising a paramagnetic 
core and a moiety configured to interact with said target biochemical molecular 
species or with molecules collectively reporting on a property of said target 
biochemical molecular species; 
c. contacting said FPP with said sample; 
d. exposing said sample to an applied magnetic field; 
e. measuring a change in a nuclear relaxation property of said sample, caused by said 
interaction between said FPP and said biochemical molecular species or said 
molecules collectively reporting on a property of said target biochemical molecular 
species; in the applied magnetic field; and, 
f. correlating said change to the presence of said biochemical molecular species in 
said sample or to at least one property correlated with the occurrence of said 
biochemical molecular species in said sample; 
2. The method according to claim 1, comprising at least one additional step; said step is 
selected from a group consisting of the following: 
performing two or more measurements to determine the relaxation time of the sample, 
wherein the measurements are performed before and after at least one addition of said 
FPP; 
detecting said target biochemical molecular species and/or characterizing at least one 
property correlated with the occurrence of said biochemical molecular species in 
vitro; 
forming said FPP as a single molecule, a multimeric system, a micro-sized vesicle or 
particle, a nano-sized vesicle or particle, a liposome, a probe or any combination 
thereof; 
selecting said sample from a group consisting of a liquid, a gas, a slurry, a liquid 
containing particulates, a gas containing particulates, a gel, a sol, a suspension, a 
solution, a dispersion, a colloid, a mixture, an emulsion, an aerosol, a liquid 
containing solid objects, a gas containing solid objects, and any combination thereof; 
selecting said sample from a group comprising a biological fluid, a biological tissue, a 
tissue extract, an industrial fluid, food sample, a beverage, wine, water, potable water, 
sewage, irrigation water, sea water, river water, lake water, industrial effluent, farm 
effluent, effluent from human habitation, road runoff, cleaning fluid, a gas sample or 
any combination thereof; 
selecting said biological fluid from a group comprising urine, blood, lymph, plasma, 
cerebrospinal fluid, saliva, amniotic fluid, bile and tears; 
providing said sample within a production process; 
selecting said production process in an industrial area, said industrial area is a member 
of a group consisting of the pharmaceuticals, food production, beverage production, 
chemical refining, chemical processing, medical products, biological products, metal 
casting, metal refining, desalination, fluid purification, and sewage processing; 
analyzing at least one characteristic or property of said target molecular species, said 
characteristic or property is selected from a group comprising concentration, 
permeability, oxidation state, redox characteristic (reduction-oxidation state), 
activation state and any combination thereof; 
applying a magnetic field, thereby enhancing the change in a paramagnetic nuclear 
relaxation property of said sample upon comparing relaxation rates at two different 
magnetic fields; 
measuring a change in a nuclear relaxation property of said sample using a portable 
NMR or MRI measuring means; 
measuring a change in a nuclear relaxation property of said sample using a magnetic 
resonance device (MRD) consisting of magnets housed within a cage; and 
measuring a change in a nuclear relaxation property of said sample using a self-
fastening cage type of a magnetic resonance device (MRD). 
3. In a self-fastening cage of a magnetic resonance device (MRD) (300), a method according 
to claim 1 comprising at least one additional step; said step is selected from a group 
consisting of: 
providing a homogeneous, stable and uniform magnetic field therein, further wherein 
said self-fastening cage type MRD additionally characterized by an outside shell 
comprising at least three flexi-jointed superimposed walls (1); 
providing an MRD characterized by an outside shell; said outside shell comprising at 
least three flexi-jointed superimposed walls (1) disposed in a predetermined clockwise 
or counterclockwise arrangement; said MRD comprising: at least six side-magnets (2) 
arranged in two equal groups being in a face-to-face orientation in a magnetic 
connection with said outside shell, increasing the overall strength of the magnetic 
field provided in said cage; at least two pole-magnet pieces (3), arranged in a face-to-
face orientation in between said side-magnets (2); at least two main-magnets (4), 
located on said pole-pieces (3), arranged in a face-to-face orientation, generating the 
static magnetic field therein said cage; and, shimming mechanism, said mechanism is 
selected from a group consisting of an array of active shim coils, passive shimming 
elements or a combination thereof; wherein at least a portion of said side-magnets (2) 
are superconductors or ferromagnets; 
providing a magnetic resonance device adapted to producing high contrast high 
resolution images of said sample; 
providing a magnetic resonance device comprising: an envelope for least partially 
confining said sample; a plurality of magnets located at least partially around said 
envelope, said plurality of magnets comprising: a least one first magnet configured to 
provide a high magnetic field for generating multiple time-resolved one or more first 
images at high resolution of at least a portion of said sample; and a least one second 
magnet configured to provide a low magnetic field for generating multiple time-
resolved one or more second images at high contrast of at least portion of same said 
sample; wherein at least one image of said first images and at least one image of said 
second images being generated in a time no greater than approximately the time 
between two first images; and, a CPU to process said images comprising a computer 
readable medium containing instructions for generating at least one third image 
superimposing at least one image of said first images with at least one image of said 
second images; 
generating multiple time resolved one or more first images at high resolution of at 
least a portion of said sample; generating multiple time resolved one or more second 
images at high contrast of at least portion of same said sample; and then 
superimposing at least one image of said first images with at least one image of said 
second images; whereby a high-contrast, high resolution real-time continuous image 
of said sample is obtained; 
selecting said at least one first magnet to be of 2 Tesla and lower; 
selecting said at least one first magnet to be of 2 Tesla and higher; 
said at least one first magnet from a group consisting of permanent magnets, 
electromagnets, superconducting magnets, and any combination thereof; 
selecting said at least one second magnet to be of 2 Tesla and lower; 
selecting said at least one second magnet to be of 2 Tesla and higher; 
selecting said at least one second magnet from a group consisting of permanent 
magnets, electromagnets, superconducting magnets, and any combination thereof; 
generating a magnetic resonance signal in the range of about 0.1 Tesla and about 10 
Tesla; 
generating a magnetic resonance signal in the range of 2 Tesla and lower; 
generating a magnetic resonance signal in the range of 2 Tesla and higher; 
applying a magnetic resonance frequency in the range of about 5 MHz to about 40 
MHz; 
selecting said magnets from a group consisting of permanent magnets, 
electromagnets, superconducting magnets, and any combination thereof; 
selecting said moiety from a group comprising antibodies, antibody fragments, 
monoclonal antibody, receptors, ligands, macromolecules, peptides, hormones, fatty 
acids, lipids, receptor agonists and antagonists, amino acids, sugars, lectins, albumins, 
polycarbon molecules, glycoproteins, nucleic acids, pegylated molecules, liposomes, 
chelators, cells, viruses, chemotherapeutic agents and any combination thereof; 
selecting said target biochemical molecular species from a group comprising a 
biological molecule, a chemical molecule, an analyte, a contaminant, a particle, a 
pathogen or any combination thereof; 
selecting said target biochemical molecular species from a group comprising a 
protein, a pathogen, a prion, a virus, a bacteria, a contaminant, a pathological isoform, 
a biomarker, an allergen, a neurotransmitter, an antigenic determinant, an epitope, a 
cell marker, cell membrane marker or epitope, a membrane marker, an enzyme, a 
chemical molecule, an analyte, a receptor, a ligand, a macromolecule, a peptide, a 
hormone, a fatty acid, a lipid, a receptor agonist and antagonist, an amino acid, a 
sugar, a glycoprotein, a nucleic acid, an antioxidant agent, a chemotherapeutic agent, 
a biological tissue and any combination thereof; 
selecting said analyte from a group comprising an organic analyte and an inorganic 
analyte; 
selecting said inorganic analyte from a group comprising molecular oxygen, oxygen-
containing radicals and combinations thereof; detecting oxygen-containing radicals 
“ad hoc” generated, for assessing the anti-oxidant properties of the sample; 
selecting said paramagnetic core as a metal ion, a metal complex, oxides of a metal 
ion, oxides of a transition metal, mixed oxides of a transition metal and their mixtures; 
selecting said paramagnetic core from a group comprising metal complexes, 
aggregates of metal complexes, polymer-bound metal complexes, stable organic 
radicals and any combination thereof; 
selecting said metal ion from a group comprising an ion of nickel, iron, manganese, 
copper, gadolinium, europium and mixtures thereof; 
assessing redox characteristics, comprising steps of detecting differences in 
Paramagnetic Relaxation Enhancement (PRE) properties induced by a change in at 
least one redox characteristic of said FPP, using an applied magnetic field; 
selecting said redox characteristic from a group comprising lipid peroxidation, lipid 
peroxidation followed by a change in membrane permeability, redox potential of 
metal ions, formation and cleavage of disulfide bonds, oxidation state, antioxidant 
activity and any combination thereof; 
providing said FPP as a liposome loaded with a plurality of paramagnetic payloads; 
applying a magnetic field, thereby enhancing a change in the permeability of said 
liposome so as to affect a nuclear relaxation property of said sample; 
applying a magnetic field, thereby enhancing a change in at least one of cleavage or 
formation of disulfide bonds of said moiety so as to affect a nuclear relaxation 
property of said sample; 
applying a magnetic field, thereby affecting at least one property of said FPP selected 
from a group comprising concentration, lipid peroxidation, membrane permeability, 
redox potential, formation and cleavage of disulfide bonds, oxidation state, redox 
potential, activation state, binding affinity, and any combination thereof, so as to 
induce a change in a nuclear relaxation property of said sample; 
conjugating said liposome with a site-specific ligand; 
conjugating said liposome with a biotin activated molecule; and 
providing said FPP as a biotinylated liposome. 
4. A method for detection of a biomarker in a sample whose main component is water, 
comprising steps of: wherein a change in T.sub.1 nuclear relaxation property is correlated to 
the presence of said biomarker in said sample. 
obtaining a sample whose main component is water; 
providing liposomes loaded with a plurality of paramagnetic agents, said liposomes 
are conjugated with a site specific moiety configured to interact with said biomarker 
in said sample; 
contacting said liposomes with said sample under conditions that allow the interaction 
between the site specific moiety and said biomarker; 
exposing said sample to an applied magnetic field; and, 
measuring a change in a nuclear relaxation property of said sample caused by said 
interaction between the liposomes and said biomarker in the applied magnetic field; 
5. The method according to claim 4, comprising additional steps of: wherein a change in 
T.sub.1 nuclear relaxation property is correlated to the presence of said biomarker in said 
sample. 
providing biotinylated liposomes; said liposomes loaded with a plurality of 
paramagnetic agents; 
providing biotinylayed ligands, said ligands configured to interact with said 
biomarker; 
providing activated avidin molecules; 
contacting said biotinylated liposomes, said biotinylayed ligands and said activated 
avidin molecules with said sample so as to enable avidin-biotin interaction, thereby 
forming complexes comprising said liposomes, said ligand and said biomarker; such 
that said complexes are specific to said biomarker; and, 
measuring a change in a nuclear relaxation property of said sample caused by said 
complex formation in the applied magnetic field; 
6. A system for detecting a target biochemical molecular species or at least one property 
correlated with the occurrence of said biochemical molecular species in a sample whose main 
component is water, comprising; wherein a change in T.sub.1 nuclear relaxation property of 
water protons in said sample measured by said MRD is correlated to the presence of said 
target biochemical molecular species and/or to the at least one property correlated with the 
occurrence of said biochemical molecular species in said sample, further wherein said FPP 
comprises a non ferrous oxide paramagnetic core. 
a. a magnetic resonance device (MRD) configured to measure a change in nuclear 
relaxation property of said sample; and, 
b. a plurality of Functionalized Paramagnetic Particles (FPP) said FPP comprising a 
paramagnetic core and a moiety configured to interact with said target biochemical 
molecular species or with molecules collectively reporting on a property of said target 
biochemical molecular species; 
7. The system according to claim 6, further comprises means for detecting said target 
biochemical molecular species and/or characterizing at least one property correlated with the 
occurrence of said biochemical molecular species in vitro. 
8. The system according to claim 6, wherein said FPP is formed as a single molecule, a 
multimeric system, a micro-sized vesicle or particle, a nano-sized vesicle or particle, a 
liposome, a probe and any combination thereof. 
9. The system according to claim 4, wherein said sample is selected from a group consisting 
of a liquid, a gas, a slurry, a liquid containing particulates, a gas containing particulates, a gel, 
a sol, a suspension, a solution, a dispersion, a colloid, a mixture, an emulsion, an aerosol, a 
liquid containing solid objects, a gas containing solid objects, and any combination thereof. 
10. The system according to claim 6, wherein said sample is further selected from a group 
comprising a biological fluid, a biological tissue, a tissue extract, an industrial fluid, food 
sample, a beverage, wine, water, potable water, sewage, irrigation water, sea water, river 
water, lake water, industrial effluent, farm effluent, effluent from human habitation, road 
runoff, cleaning fluid, a gas sample or any combination thereof. 
11. The system according to claim 10, wherein said biological fluid is selected from a group 
comprising urine, blood, lymph, plasma, cerebrospinal fluid, saliva, amniotic fluid, bile and 
tears. 
12. The system according to claim 6, wherein said sample is provided within a production 
process. 
13. The system according to claim 12, wherein said production process is in an industrial 
area, said industrial area is a member of a group consisting of the pharmaceuticals, food 
production, beverage production, chemical refining, chemical processing, medical products, 
biological products, metal casting, metal refining, desalination, fluid purification, and sewage 
processing. 
14. The system according to claim 6, wherein said property is selected from a group 
comprising concentration, permeability, oxidation state, redox characteristic (reduction-
oxidation state), activation state and any combination thereof. 
15. The system according to claim 6, wherein said magnetic resonance device (MRD) is 
configured to enhance the change in a paramagnetic nuclear relaxation property of said 
sample upon comparing relaxation rates at two different magnetic fields. 
16. The system according to claim 6, wherein said magnetic resonance device (MRD) is a 
portable NMR or MRI measuring means. 
17. The system according to claim 6, wherein said magnetic resonance device (MRD) 
consists of magnets housed within a cage. 
18. The system according to claim 6 wherein said magnetic resonance device (MRD) is a 
self-fastening cage type of a magnetic resonance device (300). 
19. In a self-fastening cage of a magnetic resonance device (MRD) (300), a system according 
to claim 6 wherein said self-fastening cage type MRD additionally characterized by an 
outside shell comprising at least three flexi-jointed superimposed walls (1). 
20. In a self-fastening cage type MRD (300), a system according to claim 6 further comprises 
a MRD characterized by an outside shell; said outside shell comprising at least three flexi-
jointed superimposed walls (1) disposed in a predetermined clockwise or counterclockwise 
arrangement; said MRD comprising: wherein at least a portion of said side-magnets (2) are 
superconductors or ferromagnets. 
a. at least six side-magnets (2) arranged in two equal groups being in a face-to-face 
orientation in a magnetic connection with said outside shell, increasing the overall 
strength of the magnetic field provided in said cage; 
b. at least two pole-magnet pieces (3), arranged in a face-to-face orientation in 
between said side-magnets (2); 
c. at least two main-magnets (4), located on said pole-pieces (3), arranged in a face-
to-face orientation, generating the static magnetic field therein said cage; and, 
d. shimming mechanism, said mechanism is selected from a group consisting of an 
array of active shim coils, passive shimming elements or a combination thereof; 
21. The system according to claim 20, wherein said MRD is configured to produce high 
contrast high resolution images of said sample. 
22. The system according to claim 20, wherein said magnetic resonance device comprising: 
a. an envelope for least partially confining said sample; 
b. a plurality of magnets located at least partially around said envelope, said plurality 
of magnets comprising: i. a least one first magnet configured to provide a high 
magnetic field for generating multiple time-resolved one or more first images at high 
resolution of at least a portion of said sample; and ii. a least one second magnet 
configured to provide a low magnetic field for generating multiple time-resolved one 
or more second images at high contrast of at least portion of same said sample; 
wherein at least one image of said first images and at least one image of said second 
images being generated in a time no greater than approximately the time between two 
first images; and, 
c. a CPU to process said images comprising a computer readable medium containing 
instructions for generating at least one third image superimposing at least one image 
of said first images with at least one image of said second images, whereby a high 
contrast, high resolution real time continues image of said sample is obtained. 
23. The system according to claim 22, wherein at least one of the following is held true: 
a. said at least one first magnet is of 2 Tesla and lower; 
b. said at least one first magnet is of 2 Tesla and higher; 
c. said at least one first magnet is selected from a group consisting of permanent 
magnets, electromagnets, superconducting magnets, and any combination thereof; 
d. said at least one second magnet is of 2 Tesla and lower; 
e. said at least one second magnet is of 2 Tesla and higher; 
f. at least one second magnet is selected from a group consisting of permanent 
magnets, electromagnets, superconducting magnets, and any combination thereof; 
g. said magnetic resonance device (MRD) is configured to generate a magnetic 
resonance signal in the range of about 0.1 Tesla and about 10 Tesla; 
h. said magnetic resonance device (MRD) is configured to generate a magnetic 
resonance signal in the range of 2 Tesla and lower; 
i. said magnetic resonance device (MRD) is configured to generate a magnetic 
resonance signal in the range of 2 Tesla and higher; 
j. said magnetic resonance device (MRD) is configured to generate a magnetic 
resonance frequency in the range of about 5 MHz to about 40 MHz; 
k. said magnets are selected from a group consisting of permanent magnets, 
electromagnets, superconducting magnets, and any combination thereof; 
l. said moiety is selected from a group comprising antibodies, antibody fragments, 
monoclonal antibody, receptors, ligands, macromolecules, peptides, hormones, fatty 
acids, lipids, receptor agonists and antagonists, amino acids, sugars, lectins, albumins, 
polycarbon molecules, glycoproteins, nucleic acids, pegylated molecules, liposomes, 
chelators, cells, viruses, chemotherapeutic agents and any combination thereof; 
m. said target biochemical molecular species is selected from a group comprising a 
biological molecule, a chemical molecule, an analyte, a contaminant, a particle, a 
pathogen or any combination thereof; 
n. said target biochemical molecular species is selected from a group comprising a 
protein, a pathogen, a prion, a virus, a bacteria, a contaminant, a pathological isoform, 
a biomarker, an allergen, a neurotransmitter, an antigenic determinant, an epitope, a 
cell marker, cell membrane marker or epitope, a membrane marker, an enzyme, a 
chemical molecule, an analyte, a receptor, a ligand, a macromolecule, a peptide, a 
hormone, a fatty acid, a lipid, a receptor agonist and antagonist, an amino acid, a 
sugar, a glycoprotein, a nucleic acid, an antioxidant agent, a chemotherapeutic agent, 
a biological tissue and any combination thereof; said analyte is selected from a group 
comprising an organic analyte and an inorganic analyte; 
o. said inorganic analyte is selected from a group comprising molecular oxygen, 
oxygen-containing radicals and combinations thereof; 
p. said oxygen-containing radicals are “ad hoc” generated radicals, for assessing the 
anti-oxidant properties of the sample; 
q. said paramagnetic core is selected from a group comprising a metal ion, a metal 
complex, oxides of a metal ion, oxides of a transition metal, mixed oxides of a 
transition metal and their mixtures; 
r. said metal ion is selected from a group comprising an ion of nickel, iron, 
manganese, copper, gadolinium, europium and mixtures thereof; 
s. said redox characteristic is selected from a group comprising lipid peroxidation, 
lipid peroxidation followed by a change in membrane permeability, redox potential of 
metal ions, formation and cleavage of disulfide bonds, oxidation state, antioxidant 
activity and any combination thereof; 
t. said FPP is a liposome loaded with a plurality of paramagnetic payloads 
u. said system further comprising means for enhancing a change in the permeability of 
said liposome so as to affect a nuclear relaxation property of said sample; 
v. said system is adapted to detect a change in at least one of cleavage or formation of 
disulfide bonds of said moiety so as to affect a nuclear relaxation property of said 
sample; 
w. said property correlated with the occurrence of said biochemical molecular species 
is selected from a group comprising concentration, lipid peroxidation, membrane 
permeability, redox potential, formation and cleavage of disulfide bonds, oxidation 
state, redox potential, activation state, binding affinity, and any combination thereof; 
x. said liposome is conjugated with a site-specific ligand; 
y. said liposome is conjugated with a biotin activated molecule; and 
z. said FPP is a biotinylated liposome. 
24. A system for detection of a biomarker in a sample whose main component is water, 
comprising: wherein a change in T.sub.1 nuclear relaxation property of the water protons in 
said sample is correlated to the presence of said biomarker in said sample. 
a. a sample whose main component is water; 
b. liposomes loaded with a plurality of paramagnetic agents, said liposomes are 
conjugated with a site specific moiety configured to interact with said biomarker in 
said sample; 
c. a magnetic resonance device (MRD) configured to measure a change in a nuclear 
relaxation property of a sample whose main component is water removed from said 
production batch or continuous flow of said FBW or biological fluid; 
25. Use of Functionalized Paramagnetic Particles (FPP) to detect the presence or at least one 
other characteristic of a target biochemical molecular species within a sample whose main 
component is water, said FPP comprising a paramagnetic core and a moiety configured to 
interact with said target biochemical molecular species or with molecules collectively 
reporting on a property of said target biochemical molecular species; wherein a change in 
T.sub.1 nuclear relaxation property of water protons within said sample measured by a 
generated applied magnetic field is correlated to the presence or at least one other 
characteristic of said target biochemical molecular species in said sample. 
26. The use according to claim 25, further adapted to detect at least one property correlated 
with the occurrence of said biochemical molecular species in said sample. 
27. A method of establishing the redox properties of a production batch or continuous flow of 
a Foodstuff, Beverage or Wine (FBW) or of a biological fluid, comprising the steps of: 
wherein a change in T.sub.1 nuclear relaxation property is correlated with the presence and/or 
concentration of said molecular oxygen or of the “ad hoc” generated radicals of said removed 
sample, thereby establishing the redox properties of said production batch or continuous flow 
of said FBW or of said biological fluid. 
a. obtaining a sample removed from said production batch or continuous flow of said 
FBW or from said biological fluid; 
b. providing Functionalized Paramagnetic Particles (FPP) configured to change their 
redox property upon interaction with dissolved molecular oxygen or “ad hoc” 
generated radicals of said removed sample; 
c. contacting said FPP with said removed sample; 
d. exposing said removed sample to an applied magnetic field; and, 
e. measuring a change in a nuclear relaxation property of said removed sample caused 
by said change in the redox properties of said FPP in the applied magnetic field; 
28. The method according to claim 27, wherein said method further comprising at least one 
step, said step is selected from a group consisting of the following: 
d. providing said FPP conjugated with at least one moiety configured to interact with 
dissolved molecular oxygen or with “ad hoc” generated radicals; 
e. selecting said moiety from a group comprising a lipid, a fatty acid, an amino acid, a 
peptide, a protein, a molecule containing at least one disulfide bond, a liposome and 
any combination thereof; 
f. measuring a change in a nuclear relaxation property of said sample caused by a 
change in the antioxidant activity of said removed sample in the applied magnetic 
field; 
g. measuring a difference in Paramagnetic Relaxation Enhancement (PRE) property 
of said removed sample caused by said interaction of said FPP with said dissolved 
molecular oxygen or with said “ad hoc” generated radicals; 
h. contacting said removed sample with FPP configured to form a liposome structure, 
said FPP comprising a paramagnetic core and a fatty acid moiety, wherein 
peroxidation of said fatty acid moiety substantially changes the permeability of said 
liposome; 
i. measuring a change in a nuclear relaxation property of said removed sample based 
on competition for molecular oxygen consumption; providing said FPP comprising a 
paramagnetic core selected from a group comprising a metal ion, a metal complex, 
oxides of a metal ion, oxides of a transition metal, mixed oxides of a transition metal 
and their mixtures; 
j. selecting said metal ion from a group comprising an ion of nickel, iron, manganese, 
copper, gadolinium, dysprosium, europium and mixtures thereof; and 
k. selecting said biological fluid from a group comprising urine, blood, lymph, 
plasma, cerebrospinal fluid, saliva, amniotic fluid, bile and tears. 
29. A system for establishing the redox properties of a production batch or continuous flow of 
a Foodstuff, Beverage, Wine (FBW) or of a biological fluid, comprising: wherein a change in 
T.sub.1 nuclear relaxation property measured by said MRD is correlated to the presence or 
concentration of dissolved molecular oxygen or “ad hoc” generated radicals of said removed 
sample, thereby the redox properties of said production batch or continuous flow of said 
FBW or of said biological fluid are established. 
l. a magnetic resonance device (MRD) configured to measure a change in a nuclear 
relaxation property of a sample removed from said production batch or continuous 
flow of said FBW or of said biological fluid; and, 
m. a plurality of Functionalized Paramagnetic Particles (FPP) configured to be in 
contact with said removed sample, said plurality of FPP are further configured to 
change at least one of their redox properties upon interaction with dissolved molecular 
oxygen or with “ad hoc” generated radicals of said removed sample; 
30. The system according to claim 29, wherein said biological fluid is selected from a group 
comprising urine, blood, lymph, plasma, cerebrospinal fluid, saliva, amniotic fluid, bile and 
tears. 
31. A system for establishing the potability of a production batch or continuous flow of a 
flowable Foodstuff, Beverage or Wine (FBW), comprising: wherein a change in T.sub.1 
nuclear relaxation property measured by said MRD correlates with dissolved molecular 
oxygen or “ad hoc” generated radicals concentration of said FBW sample, thereby 
establishing the potability of said production batch or continuous flow of said flowable FBW. 
a. a magnetic resonance device (MRD) configured to measure a change in nuclear 
relaxation property of a sample removed from said production batch or continuous 
flow of said flowable FBW; and, 
b. a plurality of functionalized paramagnetic particles (FPP) configured to be in 
contact with said sample, said plurality of FPP are further configured to change their 
redox/oxidative properties upon interaction with dissolved molecular oxygen or “ad 
hoc” generated radicals of said removed sample; 
32. The system according to claim 31, wherein at least one of the following is held true: 
a. a concentration value lower than about 6 ml of dissolved oxygen per liter of said 
removed sample is indicative of the potability of said production batch or continuous 
flow of said FBW; 
b. a value lower than X ml of oxygen per liter is correlated to >7 of the 9 point 
hedonic scale; 
c. a value lower than X ml of oxygen per liter is correlated to >y of the hybrid scale; 
and 
d. a value lower than X ml of oxygen per liter is correlated to >y of the self-adjusting 
scale. 
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